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ABBREVIATIONS 
IE: infective endocarditis. 
EHS:  Euro Heart Survey. 
VHD: valvular heart disease. 
E-BSI: Enterococcus bloodstream infection. 
TEE: transesophageal echocardiography. 
TTE: transthoracic echocardiography. 
CT: computed tomography. 
MRI: magnetic resonance imaging 
18F-FDG: 2-[18F]-fluoro-2-deoxy-D-glucose. 
PET: positron emission tomography. 
GAMES: Spanish Collaboration on Endocarditis-Grupo de Apoyo al Manejo 
de la Endocarditis Infecciosa en España 
IVDU: intra venous drug user. 
OR: odds ratio. 
CI: confidence interval. 
SD: standar deviation. 
IQR: interquartile range. 
BC: blood cultures; 
CNS: coagulase-negative staphylococci. 
MRSA: methicillin-resistant S. aureus. 
CNS: central nervous system. 
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INTRODUCTION 
Infective Endocarditis History Review 
The very term "endocarditis", referring to an individual tissue and an 
inflammatory process, goes back to early-nineteenth-century with 
clinicians such as Broussais and Bouillaud, [1]. However, it was very 
difficult during that period to define endocarditis in a simple, unequivocal 
manner[2]. Thus, the term "endocarditis" continued to be used for a 
disease which underwent endless development throughout the nineteenth 
century.  William Bart Osler (1849-1919) is the eponym linked to infective 
endocarditis in general (Osler's disease) and one of its peripheral 
manifestations (Osler's nodes). He established that blood elements such as 
fibrin and platelets deposited on the damaged endocardium - substrate of 
nonbacterial thrombotic endocardiopathy - and constituted the nucleus of 
vegetation, devaluing the concept that it depended on secretions from the 
endocardium [6]. 
Stimulated by Osler's presentations, Lord Thomas Jeeves Horder (1871-
1955)5, emphasized the pre-existence of valvulopathy and congenital 
cardiopathy, the importance of the oral and intestinal points of entry, the 
occurrence of mycotic aneurysm, the presence of splenomegaly and the 
identification of streptococcal etiology in more than 60% of the cases 
confirmed through necropsies [7]. Horder recognized five types of infective 
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endocarditis: 1 - latent; 2- fulminant; 3- acute; 4- chronic and 5- 
subacute, a modality that corresponded to 70% of the cases. 
The 20th Century and the introduction of antibiotics 
It was no after penicillin availability became universal, thanks to the 
pioneer efforts of Englishmen such as Nobel-prize winner Howard Florey 
(1898-1968) and Americans such as Martin Henry Dawson (1896-1945), 
that the treatment of infective endocarditis started an efficiency ascension 
[8]. In the 1960s, it was established that infective endocarditis was a 
curable disease. Andrew G. Wallace et al. [9] at Duke University, 
understood that the removal of the infected valve and its substitution by a 
valve prosthesis constituted an approach on the clinical manifestation 
cause. The routine surgical indication in cases of infective endocarditis in 
cases with CHF grade III/IV (the most common recommendation) reduced 
mortality from 90% to 10%. 
Introduction of imaging techniques, in the 1950s into the infective 
endocarditis field, represented a remarkable evolution in the support of the 
diagnostic rationale of infective endocarditis by joining the traditional 
clinical data and images and calculations determined by technological 
advancement in echocardiography. 
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In the 1990s, David Durack et al. [10], from Duke University gave another 
magnificent contribution to the knowledge of infective endocarditis, 
through a diagnostic systematization that elevated echocardiography as a 
determinant method of a major criterion. 
In 2000, Jennifer S. Li, a professor of Pediatrics from Duke University and 
colleagues [11] presented a perfected version of the 1994 criteria from  
Duke University; completing the outstanding advancement in the frontier 
of knowledge on infective endocarditis in the 20th century. 
 
GENERAL BACKGROUND 
The term infective endocarditis (IE) denotes infection of the endocardial 
surface of the heart and implies the physical presence of microorganisms 
in the lesion [12]. There have been several classifications for IE. 
Classically, the distinction was based on progression of the untreated 
diseases (acute – subacute – chronic)[16], but since the introduction of 
antibiotic treatment a classification based on the etiologic agent and/or 
clinical setting (native – prosthetic - device) is preferable [17]. 
IE is a severe disease with very significant morbidity. Data on mortality 
vary widely, ranging from 13% to 25% during admission, with increases of 
9% to 20% within one year after discharge [18-22].  
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EPIDEMIOLOGY 
They are no population studies on EI in Spain, so it is not possible to 
determine the exact incidence of this disease in our country; but large 
tertiary care institution studies [21] have reported an estimated incidence 
of 6.4 cases per 100,000 inhabitants per year, 0.8 cases per 1,000 
admissions and 3.5% of all episodes of significant bacteremia. 
Among hospital-based studies, IE epidemiology changed mainly in three 
aspects over the last 5 decades [20]. First, patients are significantly older 
(1980s: mean age 45.3, CI 40.2- 50.5 vs 2000s: mean age 57.2, CI 54.7- 
59.7, p<0.001). Second, more are men (1970s: 58.6%, CI 54.3- 63.0 vs 
2000s: 66.3%, CI 63.6- 69.0, p<0.01); and third, the percentage of IE cases 
occurring on prosthetic valves increased over time (1960s: 8.4%, CI -3.8- 
20.5 vs 2000s: 22.9%, CI 19.1 - 26.7, p=0.05). 
MICROBIOLOGY 
A great variety of microorganisms can cause infective endocarditis (IE); 
there have been significant changes in microbiology over time; 
Streptococcus viridans IE markedly decreased in percentage over time 
meanwhile, frequency distribution of other microorganism like 
Staphylococcus aureus IE and coagulase-negative Staphylococcus IE have 
increased. More recently, culture negative IE decreased while enterococcal 
IE percentage increased significantly over the last decade. 
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Enterococcal IE 
The enterococci are Gram-positive, facultatively anaerobic oval cocci that 
form chains of various lengths; all enterococci are in the Lancefield group 
D; they are catalase-negative and non-motile with a homofermentative 
metabolism. These microorganisms are usually able to grow at 
temperatures ranging from 10 to 45°C with optimum growth at 35 to 37°C 
[31]. 
The enterococci are commensal microorganisms that act as opportunistic 
agents causing a variety of infections in humans.  Enterococcus faecalis is 
the most common human pathogen, but Enterococcus faecium has become 
increasingly prevalent in hospital-acquired infections. All the other 
enterococcal species together constitute less than 5% of enterococcal 
infections [39, 40]. The enterococci most commonly infect the urinary 
tract, bloodstream, endocardium, burn and surgical site wounds, 
abdomen, biliary tract, and catheters and other implanted medical devices 
[16, 33]. 
Over the last decades, they have emerged from being considered virtually 
harmless bacteria to medically important multiple-antibiotic-resistant 
health care-associated pathogens that contribute significantly to patient 
morbidity and mortality as well as health care costs [28].  
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The ability to form biofilms has recently been listed among the most 
prominent virulence properties of these microorganisms, allowing 
colonization of inert and biological surfaces while protecting against 
antimicrobial substances and mediating adhesion and invasion of host 
cells [46]. Biofilm formation may be of particular importance in the 
development of endocarditis, as well as implant and other medical-device 
associated infections [28, 47, 48]. in Spain [51], up to one-third of infective 
endocarditis patients  become infected through contact with the health 
care settings. 
E. faecalis remains the more common cause of enterococcal endocarditis. 
These heart valve infections typically occur in older patients [55, 57, 58]. 
The initial source of bacteremia leading to endocarditis is usually the 
genitourinary or gastrointestinal (GI) tract. A recent large-case series of 
enterococcal endocarditis reported that between 15% and 39% are 
healthcare-associated [55, 57].  
The clinical picture of enterococcal endocarditis is usually one of subacute 
infection characterized by heart failure, rather than embolic events [57]; 
however, rapidly progressive disease can also occur. Establishing an early 
diagnosis of enterococcal IE it is essential to improve the outcome of these 
patients.  
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DIAGNOSIS 
The variability in clinical presentation of IE requires a diagnostic strategy 
that is both sensitive for disease detection and specific for its exclusion 
across all forms of the disease. In 1994, Durack and colleagues, [10] from 
Duke University Medical Center proposed a diagnostic schema termed the 
Duke criteria, which stratified patients with suspected IE into 3 categories: 
“definite”, “possible” and “rejected”  cases.    
The Duke criteria incorporated echocardiographic findings in the 
diagnostic strategy. Six common but less specific findings of IE also were 
included as minor criteria in the original Duke schema: intermittent 
bacteremia or fungemia, fever, major embolic events, non-embolic vascular 
phenomena, underlying valvular disease or injection drug use, and 
echocardiographic abnormalities that did not full fill the typical diagnosis 
of valvular vegetations, abscesses, or dehiscence. 
Therefore, IE it is diagnosed using a combination of clinical, 
microbiological, and imaging criteria [10, 12]. Failure to identify metastatic 
complications may lead to early interruption of therapy, thus triggering 
relapse and unfavorable outcome. Infectious embolisms can be 
asymptomatic and difficult to recognize [61], with the result that 
systematic performance of multiple imaging techniques (computed 
tomography [CT], magnetic resonance imaging [MRI], and ultrasonography) 
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has been recommended for all patients with IE[62]. However, this 
approach is time-consuming and cumbersome and involves frequent 
transfer of a very ill patient to the radiology department.  
2-[18F]-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography 
(PET)–CT has a promising role in infectious diseases, owing to its high 
sensitivity, anatomical precision, and lack of toxicity [64, 65]. The 
possibility of scanning the whole body with a single test is particularly 
appealing for clinicians treating patients with IE.  
Studies analyzing PET-CT for the evaluation of patients with IE are scarce, 
lack a control group, evaluate a small number of patients, or consist of 
case reports [66, 67]. The field of examination in the recent report by Saby 
et al[68] was limited to the heart, and a high incidence of false-negative 
results were detected (33%).   
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OBJECTIVES 
I.   To assess the current situation of IE in a whole country.  
1.1 To describe the changes in epidemiology and clinical 
manifestations of IE in a nationwide study. 
1.2 To evaluate the risk factors of early and late mortality of IE 
during the first five years of the study. 
 
II. To evaluate the epidemiological, microbiological, and clinical 
characteristics of Enterococcal IE  
2.1  To identify characteristics that could help to identify IE among 
patients with E-BSI 
2.2 To compared the outcome of E-BSI in patients with and 
without IE in order to assess the potential consequences of 
misdiagnosis. 
2.3 To validate the NOVA score as a model for predicting patients 
with enterococcal bloodstream infection at low risk for IE. 
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III. To evaluate the systematic performance of new diagnostic imaging 
techniques in IE patients. 
3.1 To evaluate the clinical impact of systematic whole-body 18F-
FDG PET-CT (PET-CT) for the diagnosis of septic embolisms in 
patients with IE. 
  
16 
 
MATERIAL, METHODS AND RESULTS 
I. Epidemiology and outcome of infective endocarditis in Spain. 
Since January 2008, multidisciplinary teams have prospectively 
collected all consecutive cases of IE diagnosed according to the Duke 
criteria in 25 hospitals.  Overall, 1804 patients were recruited from 
2008 to 2012 by GAMES. The median age was 69 years (IQR, 55-77), 
68.0% were men, and 37.1% of the cases were nosocomial or health 
care–related. Gram-positive microorganisms accounted for 78.8% of the 
episodes, followed by Gram-negative (5.2%), fungi (2.4%), anaerobes 
(1.2%), polymicrobial infections (1.9%), and unknown etiology (9.1%). 
Heart surgery was performed in 44.2%, and in-hospital mortality was 
28.8%. Overall, 1035 (80.6%) surviving patients had a one-year follow-
up, 69 needed heart surgery (6.6%), 32 relapsed (3.1%), and 116 died 
(11.2%; IE-related in 31-8%). The one-year independent risk factors for 
mortality were increasing age (OR, 1.02), neoplasia (OR, 2.46), renal 
insufficiency (OR, 1.59), and heart failure (OR, 4.42). Surgery was the 
only intervention that had a major impact on one-year mortality (OR, 
0.44).   
17 
 
II. Risk factors and outcome of Enterococcus infective endocarditis.   
Between September 2003 and October 2012, we performed a prospective 
cohort study (all patients with E-BSI) and a case-control study (patients 
with/without enterococcal IE) in our tertiary center.   
We detected 1515 patients with E-BSI and 65 with enterococcal IE (4.29% 
of all episodes of E-BSI, 16.7% of patients with E-BSI who underwent 
transthoracic echocardiography, and 35.5% of all patients with E-BSI who 
underwent TEE). We developed a bedside predictive score for enterococcal 
IE—NOVA score—based on the following variables: Number of positive 
blood cultures (3/3 blood cultures or the majority if more than 3), 5 
points; unknown Origin of bacteremia, 4 points; prior heart Valve disease, 
2 points; Auscultation of a heart murmur, 1 point (ROC=0.83). The best 
cutoff corresponded to a score ≥4 (sensitivity, 100%; specificity, 29%).  
A score <4 points suggested a very low risk for enterococcal IE and that 
TEE could be obviated. Depending on local prevalence of endocarditis, 
application of the NOVA score may safely obviate echocardiography in 14-
27% of patients with enterococcal bacteremia. 
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III. Clinical impact of PET-CT on the diagnosis of septic embolisms in 
patients with infective endocarditis. 
We performed a prospective cohort study (47 definite IE and PET-CT) with 
matched controls (94 definite IE patients not undergoing PET-CT) from 
January 2012 to July 2013 in a tertiary hospital. The results were 
compared with those of conventional diagnostic techniques and clinical 
follow-up.  PET-CT revealed at least 1 lesion in 35 patients (74.5%): 18 
showed an embolic complication, 8 a pathologic uptake on the valves or 
cardiac devices, 1 patient showed both, 5 had incidental non-infectious 
findings and 3 were considered false positives.  
The validity values for the efficacy of PET-CT in diagnosis of septic lesions 
were as follows: sensitivity, 100%; specificity, 80%; positive predictive 
value, 90%; and negative predictive value, 100%.PET-CT was the only 
initial positive imaging technique in 15 true-positive cases (55.5%). 
The systematic use of PET-CT was associated with a 2-fold reduction in 
the number of relapses (9.6 % vs. 4.2% p = 0.25) and enabled significantly 
more infectious complications to be diagnosed (18% vs. 57.4%; p = 
0.0001). 
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CONCLUSIONS 
I. IE remains an infrequent but severe disease that commonly 
presents in older patients with multiple underlying conditions 
and is frequently health care–related.   
 
II. Multidisciplinary groups are essential to optimize the 
management and outcome of this IE; so far, the only intervention 
that has shown a major impact on one year mortality was 
surgery. 
 
III. The prevalence of enterococcal IE depends on whether the sample 
comprised all cases among those with E-BSI (4.3%), only patients 
undergoing echocardiography (16.7%), or only patients 
undergoing TEE (35.5%).   
 
IV. Depending on the local prevalence of endocarditis, application of 
the NOVA bedside prediction score could safely obviate 
echocardiography in 14-27% of patients with enterococcal 
bacteremia. 
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V. PET-CT is an effective way of accomplishing the extension study 
in a single test in patients with IE. It is easily performed (<2 h) 
and comfortable for the patient and provides the clinician with 
whole-body data.  
 
VI. PET-CT enables significantly more infectious complications to be 
diagnosed (18.0% vs. 57.4%; p = 0.0001) and its use procured a 
trend toward a reduced number of relapses (9.6 % vs. 4.2% p = 
0.25) in patients with IE. 
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INTRODUCCIÓN 
Revisión Histórica de la Endocarditis Infecciosa 
El término "endocarditis", se refiere a un tejido individual y a un proceso 
inflamatorio, que retrocede a la primera parte del siglo diecinueve, con 
médicos como Broussais y Bouillaud, antes de que surgiera la teoría de los 
gérmenes y el nacimiento de la bacteriología [1]. Sin embargo, fue muy 
difícil durante este período definir la endocarditis de forma simple e 
inequívoca. No siempre existió una clara relación entre las ideas  y los 
argumentos eran confusos, tortuosos, circulares y no concluyentes.  
En su discusión sobre la sífilis, Ludwik Fleck, señaló que la enfermedad es 
un fenómeno cambiante que constantemente integra nueva información y 
conceptos [2]. Por lo tanto, el término "endocarditis" continúo siendo 
utilizado para definir una enfermedad que atravesó un largo proceso de 
desarrollo durante el siglo diecinueve. Simultáneamente, también 
existieron modificaciones en los vínculos etiológicos entre las anomalías 
anatómicas, los síntomas clínicos y las observaciones durante la autopsia. 
La patología de la enfermedad fue regularmente reformulada y su 
definición cambió de periodo a periodo y de país en país. La teoría de los 
gérmenes y el uso del microscopio cambio la visión y el concepto de la 
enfermedad a finales de siglo. El hecho de ser posible "ver" diminutas 
granulaciones hasta entonces invisibles no eran suficientes para 
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transformar estas granulaciones en una herramienta analítica. La 
percepción de que la enfermedad es un todo relativamente coherente con 
los síntomas etiológicos, llevaron sin embargo a la realización de 
experimentos en el laboratorio [3]. 
Hugo Ribbert (1855-1920) realizó experimentos sobre la inducción de 
endocarditis infecciosa, inyectando Staphlylococcus aureus cultivado en 
patatas, en conejos e indentifico colonias bacterianas sobre la superficie de 
las válvulas cardíacas, especialmente en la chordae tendineae de la válvula 
mitral. En el mismo año,  WK Wyssokowitsch (1854-1912), obtuvo la 
colonización de bacterias en la válvula aortica, inyectadas en el torrente 
sanguíneo de conejos a través de la arteria carótida. 
Gracias al conjunto de experimentos realizados en esa época, se 
obtuvieron dos conclusiones: a) la anterioridad de una endocardiopatía 
trombótica no bacteriana; b) la colonización del sustrato por bacterias 
circulantes. El siglo diecinueve termina con la asociación entre la lesión 
valvular, el punto de entrada y la circulación de microorganismos, la fiebre 
y las manifestaciones extra-cardíacas como la síntesis del diagnóstico de la 
endocarditis infecciosa [1, 4]. 
Al principio del siglo veinte, antes de que se vislumbraran los primero 
rayos de la esperanza terapéutica, algunos clínicos intentaron arrojar 
alguna luz, en el hasta entonces confuso conocimiento de la endocarditis y 
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superar el formidable problema de la descripción y clasificación de esta 
compleja enfermedad [5].  
William Bart Osler (1849-1919), es el epónimo general, ligado a la 
endocarditis infecciosa (enfermedad de Osler) y una de sus 
manifestaciones perifericas lleva su nombre (nódulos de Osler). Osler 
percivió que existían casos simples y otros más complejos, y por lo tanto, 
el uso de términos discriminativos como ulcerativo, maligno, séptico y 
piógeno [6]. 
Osler estableció que los elementos sanguíneos, como la fibrina y las 
plaquetas se depositaban en el endocardio dañado - sustrato de la 
endocardiopatia trombótica no bacteriana - y constituían el núcleo de la 
vegetación, devaluando el concepto de que la lesión dependía de las 
secreciones del endocardio. Osler llamó la atención hacia la diversidad de 
microorganismos involucrados en la formación de vegetaciones y recopiló 
información a favor de la característica primaria en cuanto a la presencia 
de gérmenes en la etiopatogenia de la endocarditis infecciosa, en una 
época en la que la detección de microorganismos vivos en los cultivos 
sanguíneos era incipiente [6].  
Simultáneo a la presentación de Osler, Lord Thomas Jeeves Horder (1871-
1955) enfatizó la presencia de la valvulopatía y la cardiopatía congénita, la 
importancia de los puntos de entrada orales e intestinales, la presencia de 
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aneurismas micóticos, la presencia de esplenomegalia y la identificación de 
la etiología estreptocócica en más del 60% de los casos confirmados a 
través de necropsias [7]. Horder reconoció cinco tipos de endocarditis 
infecciosa: 1 - latente; 2- fulminante; 3- aguda; 4- crónica y 5- subaguda, 
una modalidad que correspondía al 70% de los casos. 
El siglo veinte y la introducción de antibióticos 
El término "antibiótico" fue inicialmente utilizado por Selman-Abraham 
Waksman (1888-1973) en 1942, adaptándolo a la sustancia que producen 
algunos microorganismos, que antagoniza el desarrollo de otros 
microorganismos. Al inicio de la década de 1940, la sulfanilamida, un 
compuesto sintético, empezó a utilizarse en los casos de endocarditis 
infecciosa y se produjeron algunos informes de éxito terapéutico, aunque 
en la mayoría de los casos la mejoría era transitoria. No fue hasta la 
disponibilidad universal de la penicilina, gracias a los esfuerzos pioneros 
del inglés y ganador del premio Nobel, Howard Florey (1898-1968) y de los 
americanos cómo Martin Henry Dawson (1896-1945), que la eficiencia en 
el tratamiento de la endocarditis infecciosa  inició su asenso [8]. 
Sin embargo, el descenso en la mortalidad de aproximadamente un 30% 
(factor dependiente del uso de penicilina) trajo algunas preocupaciones en 
cuanto a la sobrevida de la infección y la disminución en la calidad de 
vida, debido al empeoramiento de la cardiopatia de base. Como 
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consecuencia, los dañinos efectos morfológicos de la endocarditis 
infecciosa aumentaron la investigación en los fundamentos de la 
intervención directa de aquellas lesiones valvulares severas y sintomáticas. 
 En 1960, se estableció que la endocarditis infecciosa era una enfermedad 
curable. Andrew G. Wallace et al. [9] de la Universidad de Duke, 
comprendió que la retirada de la válvula infectada y su sustitución por 
una válvula protésica, constituían un enfoque para la causa de la 
manifestación clínica. Esta innovación asistencial, marcó el inicio de la 
asociación entre la válvula protésica y la endocarditis infecciosa, ambas 
como terapéutica así como etiopatogénica (endocarditis protésica). 
Subsecuentemente, la indicación quirúrgica en casos con endocarditis 
infecciosa con insuficiencia cardiaca grado III/IV (la recomendación más 
frecuente) redujo la mortalidad al 10%. 
Gracias a los estudios de Inge Edler (1911-2001) y  Hellmuth Hertz (1920-
1990), en 1950, y la subsecuente contribución de  Harvey Feigenbaum, la 
ecocardiografía inició con el uso de la ultrasongrafía para evaluar la 
insuficiencia mitral después de la comisurotomia y el derrame pleural. La 
introducción de técnicas de imagen en el campo de la endocarditis 
infecciosa, representó una importante evolución en el apoyo de los criterios 
diagnósticos de la endocarditis infecciosa, al unir los criterios clínicos 
tradicionales y las imágenes y cálculos determinados por el avance 
tecnológico en la ecocardiografía. 
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En 1990, David Durack et al [10], de la Universidad de Duke, dio otra 
magnifica contribución en el conocimiento de la endocarditis infecciosa, a 
través de la sistematización diagnóstica, que elevó a la ecocardiografía 
como un método determinante de criterio diagnóstico mayor. Los criterios 
de la Universidad de Duke, utilizaron la estrategia de Thomas Duckett 
Jones (1899-1954) de subdividir los criterios en mayores y menores. 
Varios estudios validaron estos criterios; sin embargo se percibieron 
algunos fallos. En el año 2000, Jennifer S. Li, y colaboradores [11], 
presentaron un versión perfeccionada de los criterios de Duke de 1994, 
alcanzando un extraordinario avance en el campo de conocimiento de la 
endocarditis infecciosa del siglo veinte. 
ANTECEDENTES GENERALES 
El término endocarditis infecciosa (EI) denota una infección de la 
superficie del endocardio e implica la presencia física de microorganismos 
en la lesión [12]. Aunque en la mayoría de los casos, las más 
frecuentemente afectadas son las válvulas cardíacas, esta enfermedad 
también puede ocurrir en defectos del septo o en la pared de endocardio. 
Se ha descrito [13] que el desarrollo de la EI probablemente requiera de la 
ocurrencia simultánea de varios factores independientes e influenciados 
por el huésped. La superficie valvular debe alterarse de manera que 
produzca un lugar adecuado para la adhesión y colonización bacteriana. 
Estás alteraciones resultan en el depósito de plaquetas, fibronectina y 
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fibrina, entre otros; posteriormente las bacterias deberán alcanzar éste 
punto y adherirse e invadir el tejido involucrado, para producir la 
colonización y persistencia. Después de la colonización, la superficie es 
recubierta rápidamente con una capa protectora de fibrina y plaquetas de 
tal manera que se produzca un ambiente propicio para la posterior 
multiplicación bacteriana y crecimiento de la vegetación [14, 15]. 
Han existido varias clasificaciones de la EI. Clásicamente, la división se 
basa en una progresión de la enfermedad sin tratamiento (aguda - 
subaguda- crónica) [16], pero desde la introducción del tratamiento 
antibiótico, se prefiere una clasificación basada en el agente etiológico y/o 
cuadro clínico (nativa-protésica-dispositivo) [17]. 
La EI es una enfermedad grave con una elevada morbilidad, parcialmente 
relacionada con la necesidad cirugía cardíaca mayor, secuelas 
neurológicas y estancias hospitalarias prolongadas con tratamiento 
intravenoso. Las tasas de mortalidad presentan un amplio rango que varía 
desde el 13% al 25% durante el ingreso hospitalario, con un aumento del 
9% al 20% durante el primer año de seguimiento [18-21]. El conocimiento 
de la epidemiología de la EI es esencial, ya que diferentes organismos 
producen un gran variedad de complicaciones que requieren diferentes 
tratamientos y profilaxis.  
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EPIDEMIOLOGÍA 
A pesar de la dificultad en su evaluación, la incidencia de la EI fue 
determinada en 12.7 casos por 100,000 habitantes en un estudio realizado 
en Estados Unidos entre 1998 y 2009 [19]. El programa de vigilancia 
cardíaca europea (EHS por sus siglas en inglés), iniciado por los hallazgos 
de la Sociedad Europea de Cardiología, muestra que la endocarditis activa, 
no es una enfermedad frecuente; los pacientes con endocarditis, 
representa únicamente el 3.2% del total de la población en el programa 
EHS con enfermedad valvular (EV). Estos hallazgos son congruentes con 
los resultados de un reciente estudio de vigilancia Francés, que estimó la 
incidencia en 31 casos por millón de adultos [22]. 
 España no cuenta con estudios poblacionales, por lo que no es posible 
determinar la incidencia exacta de ésta enfermedad; pero estudios 
realizados en grandes centros hospitalarios [21] ha reportado una 
incidencia estimada de 6.4 casos por 100,000 habitantes/año, 0.8 casos 
por 1000 ingresos y 3.5% de todos los episodios de bacteremia 
significativos. 
Dentro de los estudios hospitalarios, la epidemiología de la EI ha cambiado 
principalmente en tres aspectos durante las últimas cinco décadas [20]. 
Primero, los paciente son significativamente mayores (1980: edad media 
45.3, IC 40.2- 50.5 vrs 2000: edad media 57.2, IC 54.7- 59.7, p<0.001). 
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Segundo, la mayoría de los casos son varones (1970: 58.6%, IC 54.3- 63.0 
vrs 2000: 66.3%, IC 63.6- 69.0, p<0.01); y tercero, el porcentaje de casos 
de EI sobre válvula protésica ha aumentado (1960: 8.4%, IC -3.8- 20.5 vrs 
2000: 22.9%, IC 19.1 - 26.7, p=0.05). 
 Debe de considerarse que, la EI asociada a la asistencia sanitaria, ha 
surgido de forma secundaria a la introducción de nuevas modalidades 
terapéuticas (catéteres intravenosos, marcapasos, derivaciones de diálisis, 
entre otros) y ha influenciado a la microbiología de la EI [23-25]. 
MICROBIOLOGÍA 
Existen una gran variedad de microorganismos como agentes causales de 
a endocarditis infecciosa (EI); los estafilococos y estreptococos representan 
el origen de la mayoría de los casos [26]. Sin embargo, han ocurrido varios 
cambios importantes en la microbiología a lo largo del tiempo; la tasa EI 
por Streptococcus viridans ha disminuido considerablemente (1960:27.4%, 
IC 18.4-36.4 vrs 2000: 17.6%, IC 15.7-19.5, p<0.05); mientras que la 
frecuencia de EI por otros microorganismos como el Staphylococcus aureus  
(1960: 18.1% IC 9.4- 26.7 vrs 2000s: 29.7%, IC 26.2- 33.3, p<0.05); y los 
Staphylococcus coagulasa negativa (1960: 2.4%, IC 0.8-5.5 vrs 2000: 
10.0%, IC 8.6-11.3, p<0.01) ha aumentado. 
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Datos más recientes muestra que la tasa de EI con hemocultivos negativos 
(1980s: 23.1%, CI 15.0- 31.3 vs 2000s: 14.2% CI 9.9- 18.2; p=0.01) y la 
endocarditis enterocócica (1980: 6.8%, CI 5.4- 8.2 vrs 2000: 10.5%, CI 8.9- 
12.1, p<0.001) han aumentado en las últimas décadas [20].  
Debido a que las especies de Enterococcus son una causa frecuente y en 
aumento de bacteremia en muchas instituciones [27], consideramos que 
su revisión merecen un apartado especial. 
Endocarditis Enterocócica 
El género Enterococcus incluye microorganismos que históricamente han 
sido relacionados con el género Streptococcus, y su documentación inicia 
está relacionada con la de los "estreptococos de origen fecal" o 
"enterococos". Después de la introducción de los métodos moleculares, los 
enterococos han pasado por cambios considerables en su taxonomía, que 
inició con su separación del género Streptococcus y el reconocimiento de 
los Enterococcus como un género diferente en 1984 [28].  
El continuo uso de los métodos moleculares, ha permitido grandes avances 
en la clasificación de los enterococos, que ha dado como resultado, el 
reconocimiento de 49 especies de enterococos [16, 29] 
Los enterococos son cocos Gram-positivos, anaerobios facultativos, que 
forman cadenas de varias longitudes; todos los enterococos son parte del 
grupo D de Lancefield; son catalasa negativos y no móviles. Crecen bien en 
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sodio azida, 40% de bilis, 6.5% de cloruro de sodio, y 0.1% de azul de 
metileno; hidrolizan la esculina en la presencia de sales biliares (test de 
bilis-esculina) y pueden sobrevivir a 56ºC durante 30 minutos o a un pH 
de 9.6 [28].  
Después de su incubación durante 24 horas en agar sangre, las colonias 
son usualmente de 1 a 2 mm de diámetro. Los enterococos son anaerobios 
facultativos con un metabolismo hemofermentador, que resulta en la 
producción de ácido láctico [L-(+)] como su principal producto de 
fermentación [29].  
Debido a su habilidad para fermentar una amplia gama de carbohidratos 
en ácido láctico, a los enterococos se les conoce como bacterias típicas 
acido lácticas (ALB). No producen gas. Estos microorganismos son 
usualmente capaces de crecer a temperaturas que varían de 10 a 45ºC con 
un crecimiento óptimo a 35 -  37ºC [30]. 
 Varias características intrínsecas de los enterococos les permiten crecer y 
sobrevivir bajo circunstancias difíciles y sobrevivir casi en todas partes, 
colonizando varios nichos ecológicos [31]. Estos microorganismos tienen 
una amplia distribución en la naturaleza y pueden encontrarse en la 
tierra, vegetación, agua, comida y animales.  
En los humanos, se encuentran principalmente en el tracto 
gastrointestinal y es menos frecuente encontrarlos en otros sitios como el 
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tracto genitourinario, la cavidad oral, la piel y especialmente en el área 
perineal [31]. La prevalencia de las diferentes especies de enterococos varía 
de acuerdo con el huésped y parece estar relacionado con la edad, dieta y 
otros factores que pueden estar relacionados con los cambios de las 
condiciones fisiológicas, como pueden serlo las enfermedades de base y 
tratamientos antibióticos previos.  
Los enterococos están considerados como los cocos Gram-positivos más 
abundantes que colonizan el intestino, siendo el E. faecalis una de las 
especcies bacterianas más frecuentes de este sistema [29]. Debido a que 
los enterococos son patógenos oportunista, la incidencia de cada especie 
encontrada en las infecciones humanas probablemente refleja la 
distribución de las diferentes especies de Enterococcus en el tracto 
gastrointestinal.  
Se cree que el tracto gastrointestinal representa un importante reservorio 
para las cepas asociadas con la enfermedad; esta localización les permite 
migrar y causar infecciones, así como su diseminación hacia otros 
huéspedes y el ambiente [16].  
 Por otra parte, el alto número de enterococos en la heces y su habilidad 
para resistir diferentes condiciones químicas y físicas, así como su 
habilidad para sobrevivir en el ambiente, implican que los enterococos 
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pueden ser utilizados como indicadores de contaminación fecal y como 
controles de calidad en la higiene de la comida, agua y lácteos [32]. 
La presencia de  los enterococos como miembros de la microbiota 
intestinal humana y su relación con la presencia de enterococos en la 
comida y su seguridad para el consumo humano, han sido ampliamente 
revisados [33, 34]. 
Los enterococos son microorganismos comensales que actúan como 
agentes oportunistas, provocando una gran variedad de infecciones en 
humanos. El Enterococcus faecalis es el patógeno humano más frecuente, 
sin embargo, la prevalencia del Enterococcus faecium ha aumentado 
significativamente en las infecciones relacionadas con la asistencia 
sanitaria. Todas las demás especies de enterococo representan menos del 
5% de las infecciones [35, 36]. Los sitios de infección enterocócica más 
frecuente son el tracto urinario, el torrente sanguíneo, el endocarido, 
quemaduras, infecciones de la herida quirúrgica, abdomen, tracto biliar y 
los catéteres así como otros dispositivos implantables [16, 29].  
Durante décadas, han pasado de ser considerados como bacterias 
virtualmente inocuas a ser patógenos asociados a infecciones relacionadas 
con la asistencia sanitaria con importantes mecanismos de resistencia 
antibiótica, que contribuyen significativamente en la morbi y mortalidad de 
los pacientes, así como a un aumento en el coste sanitario [27]. 
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Cambios en la dinámica entre la relación bacteria comensal y huésped, 
como los ocasionados por el uso de antibióticos de amplio espectro, daño 
en el huésped o disminución en la inmunidad del huésped, han podido 
permitir a éstas bacterias ganar acceso a sitios extra-intestinales del 
huésped y provocar infección. Por lo tanto, pacientes ancianos con 
enfermedades de base graves y otros pacientes severamente 
inmunodeprimidos con largas estancias hospitalarias, portadores de 
dispositivos invasivos y/o que han recibido tratamiento antibiótico de 
amplio espectro, son los que presentan mayor riesgo de adquirir una 
infección enterocócica [27, 37, 38]. 
 Se han identificado varios factores de potencial virulencia, que pueden 
tener un papel en la patogénesis de las infecciones enterocócicas, dentro 
de las que se incluyen: adhesinas de superficie (proteínas de superficie 
enterocócica) y sustancias de agregación (SA); secreción de toxinas 
citolisina/hemolisina, secreción de proteasas gelatinas y proteasa serina, 
antígeno A del Enterococcus faecalis (EfaA),  cápsula enterocócica, pared 
celular polisacárida y el superóxido extracelular [39-41]. Sin embargo, 
ninguna de las anteriores ha demostrado tener una contribución superior 
en la virulencia enterocócica en humanos. 
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La habilidad para formar biopelículas, recientemente ha sido considerada 
como la propiedad de virulencia más importante de éstos 
microorganismos, permitiendo la colonización de superficies  biológicas 
inertes que al mismo tiempo les protege de la acción de sustancias 
antimicrobianas y de la adhesión e invasión de células  del huésped (35). 
La formación de biopelículas puede ser de particular importancia en el 
desarrollo de endocarditis, al igual que en las infecciones relacionas con 
dispositivos médicos implantables [27, 42, 43]. 
En los hospitales de Estados Unidos, los enterococos son los segundos 
microorganismos responsables de las infecciones relacionadas con el 
catéter, del tracto urinario y de las infecciones de piel y partes blandas [44, 
45]. Sin embargo, en otros tipos de infecciones como pueden ser la 
endocarditis y la bacteriemia, los enterococos pueden claramente causar 
una infección grave y potencialmente mortal. Además, el origen de hasta 
un tercio de las endocarditis infecciosas en España [46] están relacionadas 
con la asistencia sanitaria. 
El porcentaje de pacientes con bacteriemia enterocócica que desarrollan EI 
oscila entre un 3% a un 10% [38, 47, 48]. Las diferencias en las cifras 
están parcialmente sesgados por la selección de estudios poblacionales y 
por los métodos utilizados para confirmar la endocarditis. Algunos autores 
analizan a todos los pacientes con bacteriemia enterocócica [27, 43, 49], 
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43), mientras que otros solo incluyen a los pacientes con al menos 2 
hemocultivos positivos [23, 38, 42, 50]. 
 El E. faecalis sigue siendo la causa más frecuente de endocarditis 
enterocócica. Esta afección de la válvula cardíaca, típicamente ocurre en 
pacientes ancianos [42, 51, 52]. El origen de la bacteriemia que provoca la 
endocarditis, usualmente se encuentra en el tracto genitourinario o 
gastrointestinal. La afección de las válvulas izquierdas es mucho más 
frecuente que la afección de las válvulas derechas. Se ha registrado un 
aumento significativo en la endocarditis sobre válvula protésica, lo cual 
esté probablemente relacionado con el aumento en el uso de éstas prótesis 
en adultos de edad avanzada, con un riesgo de desarrollar bacteriemia 
enterocócica significativamente mayor [42, 53]. Se ha descrito 
recientemente que entre un 15% a un 39% de los casos de endocarditis 
enterocócica, están relacionados con la asistencia sanitaria [51, 54]. El 
cuadro clínico de la endocarditis enterocócica, usualmete refleja un cuadro 
subagudo de infección, caracterizado por insuficiencia cardíaca, más que 
por eventos embolicos [51]; sin embargo, la enfermedad  progresiva rápida, 
también puede ocurrir, por lo que el diagnóstico temprano de la EI 
enterocócica es esencial para mejorar el pronóstico y frecuentemente 
requiere de la realización de un ecocardiograma transesofágico (ETE) [17, 
55]. Sin embargo, la utilización sistemática de ETE en todos los pacientes 
con bacteriemia enterocócica no está libre de complicaciones.  
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DIAGNÓSTICO 
El diagnóstico de la endocarditis debe realizarse lo antes posible para 
iniciarse el tratamiento adecuado e identificar a los pacientes con alto 
riesgo de desarrollar complicaciones, que pueden beneficiarse de un 
manejo quirúrgico precoz. 
 La variabilidad en la presentación clínica de la EI requiere de una 
estrategia diagnóstica que sea tanto sensible para la detección de la 
enfermedad y específica para su exclusión. En 1994, Durack y 
colaboradores [10] de la Universidad de Duke, propusieron un esquema 
diagnóstico llamado "los criterios de Duke", el cual clasificaba a los 
pacientes con sospecha de EI en 3 categorías: caso "definitivo" identificado 
por hallazgos clínicos o de anatomía patológica (EI probada durante la 
cirugía o autopsia); casos "posibles" (que no cumplían los criterios de 
endocarditis definitiva); y casos "rechazados" (sin evidencia patológica de 
EI durante la autopsia o cirugía, con resolución rápida del síndrome 
clínico con o sin tratamiento, o la presencia de un diagnóstico alternativo). 
El diagnóstico de la EI se basa en la presencia de criterios clínicos mayores 
o menores. Los criterios mayores de clasificación de Duke incluyen; EI 
documentada durante la cirugía o la autopsia (definición patológica) o bien 
39 
 
por criterios microbiológicos claramente definidos (bacteriemia o fungemia 
de alto grado) más datos ecocardiográficos (clínicamente definido) 
Los criterios de Duke incorporaron los hallazgos ecocardiográficos en la 
estrategia diagnóstica. La definición de criterio mayor está dada 
únicamente a 3 hallazgos ecocardiográficos: la presencia de una masa 
móvil, ecodensa adherida a la válvula o a la pared del endocardio; la 
presencia de un absceso perianular; o la presencia de una nueva 
dehiscencia sobre una válvula protésica.  
Otros seis hallazgos frecuentes, pero menos específicos también fueron 
incluidos como criterios menores al esquema original de Duke: bacteriemia 
o fungemia intermitente, fiebre, eventos embolicos mayores, fenómenos 
vasculares no embolicos, valvulopatía previa, uso de drogas por vía 
parenteral y anomalías ecocardiográficas que no cumplieran con los 
hallazgos de criterio mayor 
Por lo tanto, la EI es una enfermedad grave que cuyo diagnóstico emplea 
una combinación de criterios clínicos, microbiológicos y de imagen [12, 
16]. Sin embargo, la alta morbi y mortalidad, en parte son el resultado de 
una alta tasa (23-45%) de complicaciones embolicas a distancia [18, 21]. 
El fallo en la identificación de complicaciones metastásicas a distancia, 
puede llevar, erróneamente a la interrupción del tratamiento, 
desencadenando una recaída y pronóstico desfavorable. Los embolismos 
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infecciosos pueden ser asintomáticos y difíciles de reconocer [56], por lo 
que se recomienda el uso de múltiples técnicas de imagen [Tomografia 
Axial Computarizada (TAC), Resonancia Magnetica (RM) y ecografía ]  para 
su diagnóstico [57]. Sin embargo, éste abordaje diagnóstico conlleva a una 
considerable pérdida de tiempo, que involucra el transferir constantemente 
a un paciente severamente enfermo al departamento de radiología. 
La  2-[18F]-fluoro-2-deoxi-D-glucosa (18F-FDG) tomografía por emisión de 
positrones (PET-TAC) es una técnica de imagen que nos permite identificar 
la captación de glucosa en áreas con un aumento en la actividad 
metabólica [58] y es ampliamente utilizada en los pacientes con 
enfermedades hemato-oncológicas. Debido a su alta sensibilidad, precisión 
anatómica y carencia de toxicidad [59, 60], su uso en el campo de las 
enfermedades infecciosas es prometedor. La posibilidad de rastrear todo el 
cuerpo en una sola prueba es de particular importancia para los médicos 
que se dedican a tratar pacientes con  endocarditis infecciosa.  
Los estudios que analizan el uso del PET-TAC en la evaluación de 
pacientes con endocarditis infecciosa son escasos, carecen de grupo 
control, evalúan a un pequeño número de pacientes o consisten en la 
descripción de un único caso [61, 62]. El campo de evaluación 
recientemente realizado por Saby et al, [63] está limitado al corazón y se 
detectaron una alta tasa de falsos negativos (33%). 
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APORTACIONES 
Debido a la baja incidencia de la endocarditis infecciosa, los datos en 
cuanto a la presentación clínica, complicaciones y pronóstico han sido 
recogidos de series estudiadas durante largos periodos, realizados en un 
solo centro o durante periodos más cortos pero que involucran estudios 
multicéntricos y multinacionales. Consecuentemente los resultados, no 
necesariamente representan la situación actual de la endocarditis 
infecciosa en España, por lo que una de las principales aportaciones de la 
presente tesis doctoral es retratar la situación actual de la endocarditis 
infecciosa en España, así como presentar dos nuevas aportaciones en este 
campo: primero, el uso de un sistema de estratificación de riesgo de los 
pacientes con bacteriemia enterocócica que permite identificar a los 
pacientes con bajo riesgo de desarrollar endocarditis infecciosa; y segundo, 
el impacto clínico del uso sistemático de una técnica de imagen molecular 
(PET-TAC) para la detección de embolismos sépticos en pacientes con 
endocarditis infecciosa. 
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OBJETIVOS 
 
I.   Evaluar la situación actual de la Endocarditis Infecciosa en España. 
1.1 Describir los cambios en la epidemiología y manifestaciones 
clínicas de la EI a nivel nacional.   
1.2  Evaluar los factores de riesgo relacionados con la 
mortalidad a largo y corto plazo de la EI durante los 
primeros cinco años de nuestro estudio.   
 
II. Evaluar las características epidemiológicas, microbiológicas y clínicas 
de la endocarditis enterocócica.    
2.1  Identificar las características que puedan ayudar a identificar 
la EI entre los pacientes con bacteriemia por Enterococcus.   
2.2 Comparar el pronóstico de la bacteriemia por enterococo en 
pacientes con y sin endocarditis, para poder evaluar las 
potenciales consecuencias de su diagnóstico erróneo.  
2.3 Validar un modelo predictivo de pacientes con bacteriemia por 
enterococo con bajo riesgo de desarrollar EI.   
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III. Evaluar la realización sistemática de nuevas técnicas de imagen en 
pacientes con EI.   
3.1 Evaluar el impacto clínico del uso sistemático del 18F-FDG 
PET-CT para el diagnóstico de embolismos sépticos en pacientes 
con EI.  . 
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MATERIAL, MÉTODOS Y RESULTADOS 
I. Epidemiología y pronóstico de la endocarditis infecciosa en España. 
Desde enero 2008, varios grupos multidisciplinarios de 25 centros 
hospitalarios, han recogido de forma prospectiva todos los casos de EI 
diagnosticados de acuerdo con los criterios de Duke. En total, se 
reclutaron 1804 pacientes durante el periodo 2008-2012. La edad media 
de los casos fue de 69 años (IC, 55-77), el 68.0% eran hombres y el 37.1% 
de los casos eran nosocomiales o relacionados con la asistencia sanitaria. 
Los microorganismos Gram-positivos representaron el 78.8% de los casos, 
seguidos por los Gram-negativos (5.2%), hongos (2.4%), anaerobios (1.2%), 
infecciones polimicrobianas (1.9%) y de etiología desconocida (9.1%). Se 
realizó cirugía cardíaca en el 44.2% de los casos y la mortalidad durante el 
ingreso fue del 28.8%. En total, se completó el seguimiento al año en 1035 
(80.6%) de los pacientes que sobrevivieron, de los cuales 69 necesitaron 
cirugía cardíaca (6.6%), 32 (3.1%) tuvieron una recurrencia y 116 (11.2%; 
relacionadas con la EI 31-8%) fallecieron. 
Los factores de riesgo para la mortalidad durante el ingreso hospitalario 
fueron, la edad, antecedente de cirugía cardíaca, enfermedad 
cerebrovascular, fibrilación auricular, etiología por Staphylococcus o 
Candida, complicaciones intra cardíacas, insuficiencia cardíaca y shock 
séptico. Los factores de riesgo independientes, para la mortalidad durante 
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el año de seguimiento que se identificaron fueron: edad avanzada (OR, 
1.02), neoplasia (OR, 2.46), insuficiencia renal (OR, 1.59), e insuficiencia 
cardíaca (OR, 4.42). La única intervención que ha demostrado tener un 
mayor impacto en la mortalidad al año de seguimiento ha sido la el 
tratamiento quirúrgico (OR, 0.44). 
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II. Factores de riesgo y pronóstico de la endocarditis infecciosa por 
Enterococcus spp. 
Durante Septiembre 2003 y Octubre 2012, se realizaron dos estudios, uno 
de cohorte, prospectivo (incluyendo a todos los pacientes con BE) y otro de 
casos y controles (pacientes con y sin EI por Enterococcus spp.) en un 
centro hospitalario de nivel terciario. 
Durante el período de estudio, se detectaron 1515 pacientes con BE y 65 
casos de EI por Enterococcus spp. Los casos de endocarditis infecciosa por 
Enterococcus spp, representan el 4.29% de todos los episodios de BE, el 
16.7% de todos los pacientes con BE a los que se les realizó una 
ecocardiografía transtorácica, y el 35.5% de todos los pacientes con BE a 
los que se les realizó una ecocardiografía transesofágica.  
Posteriormente realizamos un índice predictivo de 12 puntos– NOVA score 
(por sus siglas en inglés)- para EI por Enterococcus spp, cuyas variables 
pudieran ser evaluadas a pie de cama del paciente; dichas variables 
incluyen el Número de hemocultivos positivos (3/3 hemocultivos positivos 
o la mayoría si se recogían más de 3), 5 puntos: Origen desconocido de la 
bacteriemia, 4 puntos; Enfermedad Valvular previa, 2 puntos; y 
Auscultación de un soplo cardíaco, 1 punto (COR = 0.83). El mejor punto 
de corte, corresponde a una puntuación de ≥4 (sensibilidad, 100%; 
especificidad, 29%).  
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Una puntuación <4 puntos, sugiere que el riesgo para EI por Enterococcus 
spp. es muy bajo, y por lo tanto podría evitarse la realización de una 
ecocardiografía transesofágica. Dependiendo de la prevalencia local de la 
endocarditis infecciosa, la aplicación del índice NOVA, podría de forma 
confiable, evitar la realización de una ecocardiografía en el 14-27% de los 
pacientes con bacteriemia por Enterococcus spp.  
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III. Impacto clínico del uso del 18-FDG PET-CT en el diagnóstico de 
embolismos sépticos en pacientes con endocarditis infecciosa. 
  
Estudio de cohorte prospectivo con 47 casos (EI  definitivas a los que se les 
realizó PET-TAC) y 94 controles (EI definitivas a los que no se les realizo 
PET-TAC) durante Enero 2012 a Julio 2013 en un hospital terciario. Los 
resultados del PET-TAC fueron comparados con los hallazgos de las 
pruebas de imagen convencional y el seguimiento clínico. El PET-TAC 
mostró al menos 1 lesión en 35 pacientes (74.5%): en 18 pacientes se 
encontró una complicación embolica, en 8 había una captación en las 
válvulas o dispositivos cardíacos, un paciente tenia ambos hallazgos, 5 
mostraron hallazgos incidentales no infecciosos y 3 fueron considerados 
como falsos positivos.  
Los valores de validación para la eficacia del PET-TAC en el diagnóstico de 
lesiones sépticas a distancia fueron: sensibilidad, 100%, especificidad, 
80%; valor predictivo positivo, 90%; y valor predictivo negativo, 100%. El 
PET-TAC fue la única técnica de imagen en mostrar un hallazgo positivo 
en 15 casos verdaderos positivos (55.5%). El uso sistemático del PET-TAC 
estuvo asociado a una reducción de 2 veces, en el número de recurrencias 
(9.6% vrs 4.2% p=0.25) y aumentó de manera significativa, el diagnóstico 
de complicaciones infecciosas (18% vrs 57.4%; p = 0.0001). 
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CONCLUSIONES 
I. La endocarditis infecciosa es una enfermedad infrecuente pero 
grave, que comúnmente se presenta en pacientes de edad 
avanzada, con múltiples enfermedades de base y frecuentemente 
está relacionada con la asistencia sanitaria.  
 
II. Los grupos multidisciplinarios, son esenciales para la 
optimización del manejo, tratamiento y pronóstico de esta grave 
enfermedad; la única intervención que ha demostrado tener un 
impacto en la mortalidad al año de seguimiento, es la 
intervención quirúrgica. 
 
III. La prevalencia de la endocarditis infecciosa por Enterococcus, 
depende de si se considera a todos los casos de BE (4.3%), solo a 
los pacientes a los que se les realiza una ecocardiografía (16.7%),  
o si se considera únicamente a los pacientes a los que se les 
realiza una ecocardiografía transesofágica (35.5%).  
 
IV. Dependiendo de la prevalencia local de endocarditis, la aplicación 
del índice de predicción NOVA a pie de cama del paciente, podría 
de forma confiable, evitar un 14-27% de las ecocardiografías en 
pacientes con bacteriemia por Enterococcus. 
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V. El PET-TAC es una forma efectiva de realizar el estudio de 
extensión en pacientes con EI, utilizando una sola técnica de 
imagen. Es fácil de realizar (< 2 horas), cómodo para el paciente y 
proporciona al clínico información del cuerpo completo.  
VI.  
El PET-TAC, permite el diagnóstico de significativamente más 
complicaciones infecciosas (18.0% vrs. 57.4%; p = 0.0001) y su 
utilización sistemática, muestra una tendencia hacia la reducción 
en el número de recurrencias (9.6 % vs. 4.2% p = 0.25) en 
pacientes con EI. 
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INTRODUCTION 
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Infective Endocarditis History Review 
The very term "endocarditis", referring to an individual tissue and an 
inflammatory process, goes back to early-nineteenth-century with 
clinicians such as Broussais and Bouillaud, before the germ theory and 
the birth of bacteriology [1]. However, it was very difficult during that 
period to define endocarditis in a simple, unequivocal manner. There was 
not always a clear relationship between the ideas which late historians 
have supposed fed each other; the arguments were confusing, tortuous, 
circular, and dead-end. In his discussion of syphilis, Ludwik Fleck 
correctly pointed out that disease is a constructed, ever-changing 
phenomenon which constantly integrates new information and concepts 
[2].Thus, the term "endocarditis" continued to be used for a disease which 
underwent endless development throughout the nineteenth century. There 
was also modification of the aetiological links between anatomical 
abnormalities, clinical symptoms and observations during autopsy. The 
pathology of the disease was regularly reformulated and its definition 
varied from period to period and from country to country. The germ theory 
and the use of the microscope changed the view and concept of the disease 
at the end of the century.  The fact of being able to "see" minute 
granulations hitherto invisible is not enough immediately to transform 
these granulations into an analytical tool.  
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The perception of the disease as a relatively coherent whole with 
aetiological symptoms, led, nevertheless, to laboratory experiments on 
diseases [3].  
Hugo Ribbert (1855-1920) performed experiences of infective endocarditis 
induction. He injected Staphylococcus aureus cultured in potatoes into 
rabbits and identified 
bacterial colonies 
over particles on the 
surface of heart 
valves, especially in 
the chordae 
tendineae of the 
mitral valve. In the 
same year, WK Wyssokowitsch (1854-1912) obtained the colonization of 
bacteria injected into the bloodstream of rabbits after previous 
scarification of the aortic valve via the carotid artery.  
Based on the collection of experiments in animals of the time, two 
conclusions were drawn: a) the anteriority of a nonbacterial thrombotic 
endocardiopathy; b) the colonization of this substrate by circulating 
bacteria. The 19th century ends associating valvular lesion, point of entry 
and circulation of microorganisms, fever and extra-cardiac manifestations 
under the synthetic diagnosis of infective endocarditis [1, 4].  
Hugo Ribert (1855-1920) 
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At the beginning of the twentieth century, before the dawning of the first 
rays of therapeutic hope, a few clinicians tried to shed light on the 
somewhat confused knowledge of endocarditis and to surmount the 
formidable problem of describing and classifying this complex disease [5].   
William Bart Osler (1849-1919) is the eponym linked to infective 
endocarditis in general (Osler's disease) and one of its peripheral 
manifestations (Osler's nodes).Osler 
perceived that there were simpler cases 
and more complex ones, and therefore, 
used discriminative terms such as 
ulcerative, malignant, septic and pyemic. 
He established that blood elements such 
as fibrin and platelets deposited on the 
damaged endocardium - substrate of 
nonbacterial thrombotic endocardiopathy - 
and constituted the nucleus of vegetation, 
devaluing the concept that it depended on secretions from the 
endocardium. Osler called attention to the diversity of microorganisms 
involved in the vegetation and collected evidence in favor of the primary 
characteristic of the presence of germs in the etiopathogeny of infective 
endocarditis at a time when the detection of living germs in blood cultures 
was incipient [6]. 
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Stimulated by Osler's presentations, Lord Thomas Jeeves Horder (1871-
1955)5, a physician of the sovereigns of England, emphasized the pre-
existence of valvulopathy and congenital cardiopathy, the importance of 
the oral and intestinal points of entry, the occurrence of mycotic 
aneurysm, the presence of splenomegaly and the identification of 
streptococcal etiology in more than 60% of the cases confirmed through 
necropsies [7].  
 
Horder recognized five types of infective endocarditis: 1 - latent; 2- 
fulminant; 3- acute; 4- chronic and 5- subacute, a modality that 
corresponded to 70% of the cases. 
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The 20th Century and the introduction of antibiotics 
The term "antibiotic" was initially employed by Selman-Abraham Waksman 
(1888-1973) in 1942, adapting it to a substance produced by 
microorganisms that antagonizes the development of other 
microorganisms. 
In the beginning of the 1940s, sulfanilamide, a synthetic compound, 
started to be used in infective endocarditis and determined some reports of 
therapeutic success, although most cases showed a transient benefit, but 
it was no after 
penicillin availability 
became universal, 
thanks to the pioneer 
efforts of Englishmen 
such as Nobel-prize 
winner Howard Florey 
(1898-1968) and Americans such as Martin Henry Dawson (1896-1945), 
that the treatment of infective endocarditis started an efficiency ascension 
[8]. However, the decrease in mortality to approximately 30% (penicillin-
dependent fact) brought worries concerning surviving the infection and 
quality of life impairment due to the worsening in the previous 
cardiopathy. As a consequence, the deleterious morphological effects of 
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infective endocarditis increased the research on the foundations of the 
direct intervention on the severe and symptomatic valvular lesion. 
In the 1960s, it was established that infective endocarditis was a curable 
disease. Andrew G. Wallace et al. [9] at Duke University, understood that 
the removal of the infected valve and its substitution by a valve prosthesis 
constituted an approach on the clinical manifestation cause. 
This assistential innovation marked the beginning of the association of 
valvular prosthesis and infective endocarditis, both as therapeutics and 
etiopathogeny (endocarditis in prosthesis). Subsequently, the routine 
surgical indication in cases of infective endocarditis in cases with CHF 
grade III/IV (the most common recommendation) reduced mortality from 
90% to 10%. 
Thanks to the studies by Inge Edler (1911-2001) and Hellmuth Hertz 
(1920-1990), in the 1950s and the subsequent contribution of Harvey 
Feigenbaum, the echocardiography started with the use of 
ultrasonography to evaluate mitral failure after commissurotomy and 
pericardial effusion. Introduction of 
imaging techniques into the infective 
endocarditis field, represented a  
remarkable evolution in the support of 
the diagnostic rationale of infective 
Dr. Harvey Feigenbaum 
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endocarditis by joining the traditional clinical data and images and 
calculations determined by technological advancement in 
echocardiography. 
In the 1990s, David Durack et al. [10], from Duke University gave another 
magnificent contribution to the knowledge of infective endocarditis, 
through a diagnostic systematization that elevated echocardiography as a 
determinant method of a major criterion. 
The Duke University criteria used the strategy utilized by Thomas Duckett 
Jones (1899-1954) of subdividing the criteria in major and minor ones. 
Several studies validated the new criteria; however, some gaps were 
perceived. In 2000, Jennifer S. Li, a professor of Pediatrics from Duke 
University and colleagues [11] presented a perfected version of the 1994 
criteria from  Duke University; completing the outstanding advancement in 
the frontier of knowledge on infective endocarditis in the 20th century. 
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GENERAL BACKGROUND 
The term infective endocarditis (IE) denotes infection of the endocardial 
surface of the heart and implies the physical presence of microorganisms 
in the lesion [12]. Although the heart valves are affected most commonly, 
the disease also may occur within septal defects or on the mural 
endocardium. 
It has been reported [13] that development of IE probably requires the 
simultaneous occurrence of several independent events and influenced by 
the host. The valve surface must be altered to produce a suitable site for 
bacterial attachment and colonization. These alterations result in the 
deposition of platelets, fibronectin, and fibrin, among others; then bacteria 
must reach this site and adhere to and invade the involved tissue to 
produce colonization and persistence. After colonization, the surface is 
covered rapidly with a protective sheath of fibrin and platelets to produce 
an environment conducive to further bacterial multiplication and 
vegetative growth [14, 15]. 
There have been several classifications for IE. Classically, the distinction 
was based on progression of the untreated diseases (acute – subacute – 
chronic)[16], but since the introduction of antibiotic treatment a 
classification based on the etiologic agent and/or clinical setting (native – 
prosthetic - device) is preferable [17]. 
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IE is a severe disease with very significant morbidity, which is partially, 
related to the need for major heart surgery, neurologic sequelae, and 
prolonged hospital stay with intravenous therapy. Data on mortality vary 
widely, ranging from 13% to 25% during admission, with increases of 9% 
to 20% within one year after discharge [18-22]. Proper understanding of IE 
epidemiology is essential, as different organisms produce varied 
complications and may require different treatment and prophylaxis. 
EPIDEMIOLOGY 
Although difficult to assess, its incidence was shown to be 12.7 cases per 
100,000 habitants in a study performed in the United States between 1998 
and 2009 [19]. The Euro Heart Survey (EHS) program, initiated by the 
European Society of Cardiologyfindings, show that active endocarditis is 
not a common disease: patients with endocarditis account for only 3.2% of 
the total population in the EHS on valvular heart disease (VHD). These 
findings are consistent with the incidence of IE, which was estimated at 
only 31 cases per million adults in a recent French survey [23]. They are 
no population studies on EI in Spain, so it is not possible to determine the 
exact incidence of this disease in our country; but large tertiary care 
institution studies [21] have reported an estimated incidence of 6.4 cases 
per 100,000 inhabitants per year, 0.8 cases per 1,000 admissions and 
3.5% of all episodes of significant bacteremia. 
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Among hospital-based studies, IE epidemiology changed mainly in three 
aspects over the last 5 decades [20]. First, patients are significantly older 
(1980s: mean age 45.3, CI 40.2- 50.5 vs 2000s: mean age 57.2, CI 54.7- 
59.7, p<0.001). Second, more are men (1970s: 58.6%, CI 54.3- 63.0 vs 
2000s: 66.3%, CI 63.6- 69.0, p<0.01); and third, the percentage of IE cases 
occurring on prosthetic valves increased over time (1960s: 8.4%, CI -3.8- 
20.5 vs 2000s: 22.9%, CI 19.1 - 26.7, p=0.05). 
It has to be notice that, the health care-associated IE, has emerged 
secondary to the introduction of new therapeutic modalities (intravenous 
catheters, pacemakers, dialysis shunts, among others) and has also 
influenced the microbiology of IE [24-26]. 
MICROBIOLOGY 
A great variety of microorganisms can cause infective endocarditis (IE); 
staphylococci and streptococci account for the majority of cases [27]. 
However, there have been significant changes in microbiology over time; 
Streptococcus viridans IE markedly decreased in percentage over time 
(1960s:27.4%, CI 18.4-36.4 vs 2000s: 17.6%, CI 15.7-19.5, p<0.05); 
meanwhile, frequency distribution of other microorganism like 
Staphylococcus aureus IE (1960s: 18.1% CI 9.4- 26.7 vs 2000s: 29.7%, CI 
26.2- 33.3, p<0.05);and coagulase-negative Staphylococcus IE (1960s: 
2.4%, CI 0.8-5.5 vs 2000s: 10.0%, CI 8.6-11.3, p<0.01) have increased. 
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More recently, culture negative IE decreased (1980s: 23.1%, CI 15.0- 31.3 
vs 2000s: 14.2% CI 9.9- 18.2; p=0.01) while enterococcal IE percentage 
increased significantly over the last decade (1980s: 6.8%, CI 5.4- 8.2 vs 
2000s: 10.5%, CI 8.9- 12.1, p<0.001). Because Enterococcus species is an 
increasingly common cause of bloodstream infections (E-BSI) in many 
institutions we considered it should be separately analyzed [28].  
Enterococcal IE 
The genus Enterococcus includes microorganisms that have a historical 
connection with the genus Streptococcus, and their initial documentation 
is related to the “streptococci of fecal origin” or “enterococci". After the 
introduction of molecular methods, the enterococci have undergone 
considerable changes in taxonomy, which started with the splitting of the 
genus Streptococcus and the recognition of Enterococcus as a separate 
genus in 1984. The continuous use of molecular approaches has allowed 
major developments in the classification of the enterococci, resulting in the 
recognition of 49 enterococcal species [16, 29]. 
The enterococci are Gram-positive, facultatively anaerobic oval cocci that 
form chains of various lengths; all enterococci are in the Lancefield group 
D; they are catalase-negative and non-motile. They grow well in sodium 
azide (SF broth), 40% bile, 6.5% sodium chloride, and 0.1% methylene 
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blue, they hydrolyze esculin in the presence of bile salts (bile-esculin [BE] 
test)and can survive at 56ºC for 30 minutes or at a pH of 9.6 [30].  
After growth on blood agar medium for 24 h, colonies are usually between 
1 and 2 mm in diameter. Enterococci are facultative anaerobes with a 
homofermentative metabolism that results in the production of L-(+)-lactic 
acid as the major end product of glucose fermentation [29]. Because of 
their ability to ferment a wide range of carbohydrates to lactic acid, the 
enterococci are referred to as typical lactic acid bacteria (LAB). Gas is not 
produced. These microorganisms are usually able to grow at temperatures 
ranging from 10 to 45°C with optimum growth at 35 to 37°C [31]. 
Several intrinsic characteristics of the enterococci allow them to grow and 
survive under harsh conditions and persist almost everywhere, colonizing 
several ecological niches [32]. These microorganisms are widespread in 
nature and can be found in soil, plants, water, food, and animals. In 
humans, they are predominantly inhabitants of the gastrointestinal tract 
and are less commonly found in other sites, such as the genitourinary 
tract, the oral cavity, and skin, especially in the perineal area [32]. The 
prevalence of the different enterococcal species appears to vary according 
to the host and is also influenced by age, diet, and other factors that may 
be related to changes in physiologic conditions, such as underlying 
diseases and prior antimicrobial therapy. Enterococci are considered 
among the most abundant Gram-positive cocci colonizing the intestine, 
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with E. faecalis being one of the most common bacterial species recovered 
from this site [33]. Since the enterococci are opportunistic pathogens, the 
incidence of each species found in human infections probably reflects the 
distribution of the different species of Enterococcus in the human 
gastrointestinal tract. This site is believed to represent an important 
reservoir for strains associated with disease; from this location, they may 
migrate to cause infections and can also disseminate to other hosts and to 
the environment [16].  
On the other hand, the occurrence of high numbers of enterococci in the 
feces and their ability to resist different chemical and physical conditions 
and to survive in the environment imply that the enterococci can be used 
as indicators of fecal contamination and of the hygienic quality of food, 
milk, and drinking water [34]. The occurrence of enterococci as members 
of the intestinal microbiota of humans and the relationship between the 
presence of enterococci in foods and human safety have been extensively 
reviewed [35-38]. 
The enterococci are commensal microorganisms that act as opportunistic 
agents causing a variety of infections in humans.  Enterococcus faecalis is 
the most common human pathogen, but Enterococcus faecium has become 
increasingly prevalent in hospital-acquired infections. All the other 
enterococcal species together constitute less than 5% of enterococcal 
infections [39, 40]. These other species associated with human infections 
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include Enterococcus gallinarum, Enterococcus casseliflavus, Enterococcus 
avium, Enterococcus cecorum, Enterococcus durans, Enterococcus hirae, 
Enterococcus malodoratus, Enterococcus mundtii, Enterococcus 
pseudoavium and Enterococcus raffinosus. 
The enterococci most commonly infect the urinary tract, bloodstream, 
endocardium, burn and surgical site wounds, abdomen, biliary tract, and 
catheters and other implanted medical devices [16, 33]. 
Over the last decades, they have emerged from being considered virtually 
harmless bacteria to medically important multiple-antibiotic-resistant 
health care-associated pathogens that contribute significantly to patient 
morbidity and mortality as well as health care costs [28]. Changes in the 
dynamics of the commensal host-bacterial relationship, such as those 
promoted by the use of broad-spectrum antibiotics, host injury, or 
diminished host immunity, could allow these bacteria to gain access to 
extraintestinal host sites and cause infection. Therefore, elderly patients 
with serious underlying diseases and other severely ill 
immunocompromised patients who have been hospitalized for prolonged 
periods, have been treated with invasive devices, and/or have received 
broad-spectrum antimicrobial therapy are at higher risk to acquire 
enterococcal infections [28, 41, 42]. 
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Several potential virulence factors that may play a role in the pathogenesis 
of enterococcal infections have been identified in enterococcal isolates, 
including the surface adhesinsEsp (Enterococcal surface protein) and 
aggregation substance (AS), secreted toxin cytolysin/hemolysin, secreted 
proteases gelatinase and serine protease, MSCRAMM Ace (Adhesin to 
collagen of E. faecalis), E. faecalis antigen A (EfaA), enterococcal capsule, 
cell wall polysaccharides, and extracellular superoxide [43-45]. 
Nevertheless, none has been established as making a major contribution 
to enterococcal virulence in humans. 
The ability to form biofilms has recently been listed among the most 
prominent virulence properties of these microorganisms, allowing 
colonization of inert and biological surfaces while protecting against 
antimicrobial substances and mediating adhesion and invasion of host 
cells [46]. Biofilm formation may be of particular importance in the 
development of endocarditis, as well as implant and other medical-
deviceassociated infections [28, 47, 48]. 
In hospitals in the United States, enterococci are the second most common 
organisms recovered from catheter-associated infections of the 
bloodstream and urinary tract, and from skin and soft-tissue infections 
[49, 50].However, for other types of infections, most notably endocarditis 
and bacteremia, enterococci can clearly cause serious and often life-
threatening disease. In addition, up to one-third of infective endocarditis 
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patients in Spain [51] become infected through contact with the health 
care settings. 
The percentage of patients with E-BSI who have infective endocarditis (IE) 
is estimated to be between 3% and 10% [42, 52, 53]. The differences in 
these values are at least partially biased by the study population selected 
and by the methods used to confirm endocarditis. Some authors analyzed 
all patients with E-BSI [28, 48, 54], whereas others only included patients 
with at least 2 positive blood cultures [24, 42, 55, 56].  
E. faecalis remains the more common cause of enterococcal endocarditis 
than E. faecium. These heart valve infections typically occur in older 
patients [55, 57, 58]. The initial source of bacteremia leading to 
endocarditis is usually the genitourinary or gastrointestinal (GI) tract. Left-
sided involvement is much more common than right-sided involvement. 
Prosthetic valve enterococcal endocarditis has been increasingly noted, 
which is perhaps related to the increasing use of these prostheses in older 
adults who are at an inherently higher risk for enterococcal bacteremia 
[55, 59]. In one retrospective analysis of a large endocarditis database [55], 
an equal number of women and men had enterococcal endocarditis, 
although enterococcal endocarditis is typically reported more often in men 
than women [57]. A recent large-case series of enterococcal endocarditis 
reported that between 15% and 39% are healthcare-associated [55, 57].  
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The clinical picture of enterococcal endocarditis is usually one of subacute 
infection characterized by heart failure, rather than embolic events [57]; 
however, rapidly progressive disease can also occur. 
Establishing an early diagnosis of enterococcal IE it is essential to improve 
the outcome of these patients and most frequently requires 
transesophagealechocardiography (TEE) [17, 60]. However, using TEE in 
all patients with E-BSI is far from easy, costly, time-consuming, and 
subject to complications. 
DIAGNOSIS 
The diagnosis of endocarditis must be made as soon as possible to initiate 
therapy and identify patients at high risk for complications who may be 
best managed by early surgery. 
The variability in clinical presentation of IE requires a diagnostic strategy 
that is both sensitive for disease detection and specific for its exclusion 
across all forms of the disease. In 1994, Durack and colleagues, [10] from 
Duke University Medical Center proposed a diagnostic schema termed the 
Duke criteria, which stratified patients with suspected IE into 3 categories: 
“definite” cases, identified either clinically or pathologically (IE proved at 
surgery or autopsy); “possible” cases (not meeting the criteria for definite 
IE); and “rejected” cases (no pathological evidence of IE at autopsy or 
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surgery, rapid resolution of the clinical syndrome with either no treatment 
or short-term antibiotic therapy, or a firm alternative diagnosis). 
A diagnosis of IE is based on the presence of either major or minor clinical 
criteria. Major criteria in the Duke strategy included IE documented by 
data obtained at the time of open heart surgery or autopsy (pathologically 
definite) or by well-defined microbiological criteria (high-grade bacteremia 
or fungemia) plus echocardiographic data (clinically definite). 
The Duke criteria incorporated echocardiographic findings in the 
diagnostic strategy. Major diagnostic weight was given to only 3 typical 
echocardiographic findings: mobile, echodense masses attached to valvular 
leaflets or mural endocardium; periannular abscesses; or new dehiscence 
of a valvular prosthesis. 
Six common but less specific findings of IE also were included as minor 
criteria in the original Duke schema: intermittent bacteremia or fungemia, 
fever, major embolic events, non-embolic vascular phenomena, underlying 
valvular disease or injection drug use, and echocardiographic 
abnormalities that did not full fill the typical diagnosis of valvular 
vegetations, abscesses, or dehiscence. 
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Therefore, IE is a severe disease that is diagnosed using a combination of 
clinical, microbiological, and imaging criteria [10, 12].However, morbidity 
and mortality are significant, in part as a result of the high rate of distant 
embolic complications (23-45%) [18, 21].  
 Failure to identify metastatic complications may lead to early interruption 
of therapy, thus triggering relapse and unfavorable outcome. Infectious 
embolisms can be asymptomatic and difficult to recognize [61], with the 
result that systematic performance of multiple imaging techniques 
(computed tomography [CT], magnetic resonance imaging [MRI], and 
ultrasonography) has been recommended for all patients with IE[62]. 
However, this approach is time-consuming and cumbersome and involves 
frequent transfer of a very ill patient to the radiology department.  
2-[18F]-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography 
(PET)–CT is widely used in patients with onco-hematological conditions, 
since it can identify glucose uptake in areas with increased metabolic rate 
[63]. It has a promising role in infectious diseases, owing to its high 
sensitivity, anatomical precision, and lack of toxicity [64, 65]. The 
possibility of scanning the whole body with a single test is particularly 
appealing for clinicians treating patients with IE.  
Studies analyzing PET-CT for the evaluation of patients with IE are scarce, 
lack a control group, evaluate a small number of patients, or consist of 
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case reports [66, 67]. The field of examination in the recent report by Saby 
et al[68] was limited to the heart, and a high incidence of false-negative 
results were detected (33%).   
 
Shortage in the literature 
Overall, due to the low incidence of IE, data on clinical presentation, 
complications, and outcome are from series collected over prolonged 
periods, in single centers, or over shorter periods in multicenter, 
multinational studies. Consequently, they do not necessarily represent the 
current situation in Spain. Hence arising the need to create an infective 
endocarditis study group. 
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GAMES STUDY GROUP 
The Spanish collaboration on endocarditis (GAMES) consists of 
multidisciplinary groups dedicated to improving the management of IE. 
These hospital-based endocarditis groups usually include microbiologists, 
infectious disease physicians, echocardiographers, heart surgeons, and 
cardiologists. Centers with no cardiac surgery unit had to be able to follow 
patients referred elsewhere for surgery. These groups prospectively 
recorded all consecutive episodes of IE at their institutions and collected 
the data according to a pre-established clinical form with common 
standard definitions 
[10, 16, 17]. At 
discharge, the clinical 
forms were sent to the 
coordinating center or 
data were entered 
directly by the 
investigators through a 
secure data entry 
system. In the 
coordinating center, specialized clinicians and data managers reviewed the 
data for accuracy and contacted the referring centers, if necessary, for 
queries and clarifications. Enrollment began in January 2008. 
GAMES participating regions centers. 
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DEFINITIONS 
IE was defined according to the modified Duke criteria [10]. Episodes were 
classified into four distinct categories representing different populations: 
native valve IE in intravenous drug users (IVDU), native valve IE in non-
IVDU, prosthetic valve IE, and IE on a cardiac device.  
Site of IE acquisition was defined following ICE recommendations [17]. In 
brief, community-acquired IE was defined as IE diagnosed within the first 
48 hours of admission in a patient who did not fulfill the criteria for 
nosocomial or health care–associated infection. Nosocomial IE was defined 
as IE in a patient who had been hospitalized for more than 48 hours before 
the onset of signs or symptoms consistent with IE. Health care–associated 
IE was an IE diagnosed within 48 hours of admission of an outpatient with 
any of the following criteria: intravenous therapy, wound care, or 
specialized nursing care at home within the 30 days before the onset of IE; 
attendance at a hospital or hemodialysis clinic or receipt of intravenous 
chemotherapy within the 30 days before the onset of IE; hospitalization in 
an acute care hospital for two or more days during the 90 days before the 
onset of IE; or residence in a nursing home or long-term care facility[69]. 
A cardiac device was defined as a permanent pacemaker and/or 
cardioverter-defibrillator. 
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Perivalvular extension was considered to be substantial when abscesses 
were present or other echocardiography findings suggested that the 
infection was invasive (communication between chambers, wall dissection, 
or large valvular dehiscence). Prosthetic valve IE was defined as infection 
occurring on any type of non-native tissue or mechanical device. The 
EuroSCORE20 was used to assess operative risk [70, 71]. 
We used the Charlson comorbidity index as a method of estimating the 
risk of death from comorbid disease [72]. 
Chronic immunosuppressive therapy was defined as the administration of 
recognized immunosuppressive agents for more than 30 days at the time 
of IE diagnosis. 
CNS event defined as an acute neurological deficit of vascular etiology 
lasting more than 24 hours [73]. Systemic embolization was defined as an 
embolic event outside of the central nervous system. Congestive heart 
failure was defined according to the New York Heart Association 
classification system [74]. 
Intra-cardiac complications were based on echocardiography findings 
(communication between chambers, wall dissection abscess or 
dehiscence). 
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OBJECTIVES 
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I.   To assess the current situation of IE in a whole country.  
1.1 To describe the changes in epidemiology and clinical 
manifestations of IE in a nationwide study. 
1.2 To evaluate the risk factors of early and late mortality of IE 
during the first five years of the study. 
 
II. To evaluate the epidemiological, microbiological, and clinical 
characteristics of Enterococcal IE  
2.1  To identify characteristics that could help to identify IE among 
patients with E-BSI 
2.2 To compared the outcome of E-BSI in patients with and 
without IE in order to assess the potential consequences of 
misdiagnosis. 
2.3 To validate the NOVA score as a model for predicting patients 
with enterococcal bloodstream infection at low risk for IE. 
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III. To evaluate the systematic performance of new diagnostic imaging 
techniques in IE patients. 
3.1 To evaluate the clinical impact of systematic whole-body 18F-
FDG PET-CT (PET-CT) for the diagnosis of septic embolisms in 
patients with IE. 
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MATERIAL, METHODS AND RESULTS 
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I. Current situation of Infective Endocarditis in Spain 
The study sample comprised all consecutive patients with IE in the 25 
centers from January 1st, 2008 to December 31st, 2012. GAMES consists 
of multidisciplinary groups dedicated to improving the management of IE. 
These hospital-based endocarditis groups include microbiologists, 
infectious disease physicians, heart surgeons, imaging and clinical, 
cardiologists. Centers without cardiac surgery unit had to be able to follow 
patients referred elsewhere for surgery. These groups prospectively 
recorded all consecutive episodes of IE at their institutions and collected 
the data according to a pre-established clinical form with common 
standard definitions. [10-12] At discharge, the clinical forms were sent to 
the coordinating center or data were entered directly by the investigators 
through a secure data entry system. In the coordinating center, specialized 
clinicians and data managers reviewed the data for accuracy and 
contacted the referring centers, if necessary, for queries and clarifications. 
Enrollment began in January 2008. This report includes data from the 
first 1804 consecutive cases collected. Patients were followed for one year. 
Because of the differences in clinical setting and outcome, we classified IE 
episodes as follows: native valve in non-IVDU, native valve in IVDU, 
prosthetic valve and IE involving cardiac devices. 
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In order to provide practical information to clinicians, the four classic 
types of IE were compared: native valve IE in IVDU and in non-IVDU, 
prosthetic valve IE, and IE affecting intra-cardiac devices.  
 
Statistical analysis 
Quantitative variables were expressed as mean ± SD or as medians with 
IQR, as appropriate; qualitative variables were expressed as frequency and 
percentage. Continuous variables were compared using the t test, and 
categorical variables were compared using the chi-square test or Fisher 
exact test when the chi-square test was not appropriate. Adjusted odds 
ratios were computed using logistic regression analysis. Stepwise logistic 
regression analysis was performed including variables with a p value ≤0.1 
in the univariate analysis. All statistical analyses were performed using 
SPSS software version 18 (IBM PASW Statistics 18.0, Armonk, New York, 
USA). 
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Incidence of IE 
The 25 centres that participated in this study are located throughout 
Spain and attend an estimated population of 10,218,634 habitants, ie, 
21.7% of the Spanish population [75]. Therefore, we estimated an annual 
incidence of at least 3.5 cases of IE per 100,000 inhabitants. 
General characteristics of the cohort 
From January 2008 to December 2012, a total of 1804 cases were 
diagnosed. Patients surviving the initial admission were followed for one 
year. Enrolment from the participating centers was widely distributed. The 
median age of the cohort was 69 years (IQR, 55-77; mean, 65.1), and 1228 
(68.0%) patients were male. The most common underlying conditions are 
summarized in table 1. The main conditions were previous cardiac surgery 
(620, 34.4%); heart failure (531, 29.4%), and diabetes mellitus (471, 
26.1%). Other comorbidities that were not as frequent but nevertheless 
had a high impact on clinical course were previous IE episode (126, 6.9%), 
hemodialysis (79, 4.4%), HIV infection (39, 2.2%), and transplantation (27, 
1.5%).  The mean Charlson-age corrected comorbidity Index was 4.49±2.6.  
The most common predisposing conditions were degenerative native valve 
disease (41.8%) followed by prosthetic valves (29%), rheumatic valve 
disease (8.0%), intravenous catheter (7.5%), and congenital heart disease 
(3.2%). 
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Table 1. Epidemiological and clinical characteristics of 1804 episodes of infective endocarditis prospectively collected in Spain. 
 
TOTAL 
Native non-
IVDU 
Native IVDU Prosthetic Device p 
  N=1804 N=1079 N=52 N=504 N=169   
Median age (IQR) 69  (57 - 77) 68.7 (55-77) 39.9 (33.–45) 71.1 (61 - 77) 71.4 (60-78) <.01 
Male (%) 1228 (68.1) 728 (67.5) 42 (82.4) 337 (67.0) 121 (71.6) 0.10 
Underlyingconditions       
Heartfailure 531 (29.4) 252 (23.6) 0 203 (40.7) 76 (46.3) <.01 
Previouscardiacsurgery 620 (34.4) 95 (8.9) 1 (2.0) 488 (97.2) 36 (21.4) <.01 
Diabetes mellitus 471 (26.1) 289 (26.8) 1 (1.9) 131 (26.0) 50 (29.8) <.01 
Mild renal insufficiency 188 (10.4) 88 (8.2) 1 (2.0) 70 (14.0) 29 (17.3) <.01 
Severe renal insufficiency 280 (15.5) 168 (15.7) 5 (9.8) 73 (14.5) 34 (20.1) .22 
Atrial fibrillation 457 (25.3) 190 (17.9) 0 219 (44.4) 48 (29.1) <.01 
Lungdisease 312 (17.3) 189 (18.0) 2 (3.9) 90 (18.2) 31 (18.9) .07 
Neoplasm 290 (16.1) 203 (18.9) 0 69 (13.7) 18 (10.7) <.01 
HIV infection 39 (2.2) 13 (1.2) 23 (44.2) 3 (0.6) 0 <.01 
Previous IE 126 (7.0) 43 (4.0) 6 (11.5) 64 (12.8) 13 (7.8) <.01 
Charlson-ageindex 4.49 (2.6) 4.46 2.92 4.57 4.92 <.01 
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TOTAL 
N=1804 
Native non-
IVDU 
N=1079 
Native IVDU 
N=52 
Prosthetic 
N=504 
Device 
N=169 
p 
Transferredfromother hospital 479 (26.6) 281 (26.0) 13 (25.0) 139 (27.6 46 (27.2) .91 
Symptoms before admission (median 
days; IQR) 
21 (7-60) 14 (5-55) 7 (4-21) 7 (3-21) 8 (5-60) .58 
Mitral 808 (44.8) 579 (53.7) 14 (26.9) 211 (41.9) 4 (2.4) <.01 
Tricuspid 99 (5.5) 58 (5.4) 24 (46.2) 4 (0.8) 13 (7.7 <.01 
Pulmonary 29 (1.6) 16 (1.5) 3 (5.8) 8 (1.6) 2 (1.2) .11 
Site of acquisition       
Nosocomial 507 (28.1) 241 (23.1) 1 (1.9) 190 (39.7) 75 (46.9) <.01 
Community-acquired 1061 (58.8) 701 (67.3) 49 (94.2) 251 (52.6) 60 (37.7) <.01 
HCR 162 (9.0) 100 (9.6) 2 (3.8) 36 (7.5) 24 (15.1) .01 
Presentation       
Fever>38°C 1506 (83.4) 899 (84.0) 43 (84.3) 427 (85.9) 137 (82.0) .01 
Splinterhemorrhages 41 (2.3) 34 (11.0) 4 (16.0) 3 (2.7) - .01 
Oslernodes 35 (1.9) 27 (8.4) 2 (7.7) 6 (5.0) - .38 
Janewaylesions 43 (2.4) 29 (9.5) 4 (16.0) 9 (8.0) 1 (6.3) .63 
Roth spots 18 (1.0) 13 (4.5) 1 (4.0) 4 (3.8) - .84 
Splenomegaly 209 (11.6) 140 (13.7) 16 (31.4) 46 (9.5) 7 (4.3) <0.01 
New murmur 577 (32.0) 430 (44.8) 23 (50.0) 115 (26.4) 9 (5.7) <0.01 
Worsening of oldmurmur 221 (12.3) 138 (16.3) 2 (4.7) 74 (18.4) 7 (4.5) <0.01 
Mean CRP (SD) 61.5 (87.2) 65.8 (90.2) 37.2 (68.0) 55.2 (84.9) 60.9 (79.1) .015 
Elevated RF 160 (8.9) 104 (25.8) 5 (26.3) 33 (17.8) 18 (26.1) .18 
CRP,C reactive protein; IE, infective endocarditis; HCR, health care–related; RF, rheumatoid factor.
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Affected valve. Most of the patients (62.7%) had native valve IE, and 
most episodes were left-sided (mitral 808 [44.8%] and aortic valves 852 
[47.2%]). The tricuspid valve was involved in 99 cases (5.5%) and the 
pulmonary valve in 29 cases (1.6%). Prosthetic valve endocarditis 
occurred in 504 cases (27.9%) and device-related endocarditis in 169 
patients (9.3%).  
The site of acquisition was determined in 95.9% of patients (Table 1); 
28.1% episodes were classified as nosocomial. In total, 479 patients 
(26.6%) were transferred from another hospital. In the case of 
community-acquired episodes, most patients (86%) were admitted 
within 1 month of the initial signs of illness (12.6% at 1-3 months and 
6.3% >3 months).  
Clinical manifestations are listed in table 1. It is noteworthy that the 
classic signs of IE were uncommon. These included splenomegaly 
(11.6%), splinter hemorrhages (2.3%), Janeway spots (2.4%), and Osler 
nodes (1.9%). However, patients with IE had other common 
manifestations (respiratory [41%], renal [39%], neurological [19.7%], 
osteoarticular [11.5%], and ocular [6.3%]).  
Etiology. Most episodes (78.8%) were caused by Gram-positive 
microorganisms, followed by Gram-negative microorganisms (5.2%), 
fungi (2.4%), anaerobes (1.2%), and polymicrobial infections (1.9%). The 
distribution of the most common microorganisms is shown in table 2. 
Twenty-two episodes were caused by microorganisms of the HACEK 
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group. Other fastidious microorganisms included Coxiella burnetii (15), 
Listeria monocytogenes (6), Tropheryma whipplei (5), Bartonella spp (4), 
and Brucella melitensis (1). Accordingly, the rate of unknown etiology of 
endocarditis was 9.1%. 
Diagnosis. Blood cultures were obtained in 1787 patients (99.1%) and 
provided the etiology in 1523 (85.3%). Of the 264 patients (14.7%) with 
negative blood cultures, 34% had received antimicrobial agents in the 
previous week. An etiologic diagnosis was achieved in 106 cases with a 
combination of the following techniques: heart valve PCR (34; 20.7%), 
serology (99; 60.3%), and extracardiac cultures (59; 35.9%).    
Transesophageal echocardiography was used in most patients (76.3%), 
and 1148 (83.4%) presented vegetations. Abscess was the most common 
paravalvular complication (27.8% of patients), whereas 26.6% of 
patients with prosthetic valve IE had evidence of a prosthetic valve 
complication such as dehiscence or new paravalvular regurgitation. 
Comparison of the four types of IE 
Overall, IE episodes were classified as follows: native valve in non-IVDU 
(n=1079), native valve in IVDU (n=52), prosthetic valve (n=504), and IE 
involving cardiac devices (n=169) (Tables 1 and 2).  
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Table 2.Etiology, diagnosis, and outcome of 1,804 episodes of infective endocarditis prospectively collected in Spain. 
 
TOTAL 
N=1804 
Native non-IVDU 
N=1079 
Native IVDU 
N=52 
Prosthetic 
N=504 
Device 
N=169 
p 
Definite IE 1498 (83.0) 919 (85.6) 48 (92.3) 409 (81.3) 122 (72.2) <0.01 
Possible IE  300 (16.6) 155 (14.4) 4 (7.7) 94 (18.7) 47 (27.8) <0.01 
Etiology 
Staphylococcusspp 
 
728 (40.3) 
 
382 (35.3) 
 
30 (55.8) 
 
218 (43.2) 
 
98 (58.0) 
 
<0.01 
    S. aureus 426 (23.6) 278 (25.8) 26 (50.0) 77 (15.3) 45 (26.6) <0.01 
    MRSA 66 (3.7) 43 (4.0) 2 (3.8) 13 (2.6) 8 (4.7) .46 
    CNS 302 (16.7) 104 (9.7) 4 (7.7) 141 (28.0) 53 (31.5) <0.01 
Streptococcusspp. 440 (24.4) 329 (30.5) 8 (15.4) 86 (17.1) 17 (10.1) <0.01 
     S. bovis 117 (6.4) 80 (7.4) 0 32 (6.5) 5 (3.0) 0.036 
     S. viridans 
     Others 
223 (12.3) 
100 (5.5) 
171 (16.0) 
79 (7.3) 
7 (13.5) 
1 (1.9) 
38 (7.5) 
15 (3.0) 
7 (4.1) 
5 (5.3) 
<0.01 
0.001 
Enterococcusspp. 230 (12.7) 142 (13.2) 5 (9.6) 77 (15.3) 6 (3.6) .001 
Other Gram + 26 (1.4) 14 (1.3) 2 (3.8) 8 (1.5) 2 (1.1) .48 
    Gram - 93 (5.2) 53 (4.9) - 25 (5.0) 15 (8.9) 0.05 
Fungi 44 (2.4) 21 (1.9) 2 (3.8) 15 (3.0) 6 (3.6) .38 
Negative BC 164 (9.1) 100 (9.3) 5 (9.6) 48 (9.5) 11 (6.5) .67 
Vegetations 1284 (71.2) 836 (77.6) 41 (78.8) 296 (58.8) 111 (65.7) <0.01 
Intracardiaccomplication 501 (27.8) 309 (28.9) 9 (17.6) 171 (33.9) 12 (7.1) <0.01 
TEE 1377 (76.3) 776 (72.0) 23 (44.2) 450 (89.3) 128 (76.2) <0.01 
Clinicalcourse       
Embolisms 525 (29.1) 322 (30.5) 30 (60.0) 143 (28.9) 30 (18.2) <0.01 
New heartfailure 698 (38.7) 488 (45.9) 15 (29.4) 214 (43.2) 32 (19.2) <0.01 
Persistent BSI 151 (8.4) 90 (8.6) 1 (2.0) 45 (9.2) 15 (9.0) .37 
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TOTAL 
N=1804 
Native non-IVDU 
N=1079 
Native IVDU 
N=52 
Prosthetic 
N=504 
Device 
N=169 
p 
Surgery       
Indicated  (%) 1152 (63.9) 661 (61.4) 25 (48.1) 341 (67.7) 125 (74.0) <0.01 
Performed (%) 797 (44.2) 452 (41.9) 15 (28.8) 220 (43.8) 110 (65.1) <0.01 
Reasonsforsurgery       
Cardiacinsufficiency 373 (20.7) 257 (25.9) 6 (13.0) 104 (22.3) 6 (3.7) <0.01 
Earlyprosthetic IE 78 (4.3) 8 (0.8) 1 (2.2) 67 (14.4) 2 (1.2) <0.01 
    Late prosthetic IE 78 (4.3) 1 (0.1) - 74 (15.9) 3 (1.8) <0.01 
    Valvular insuf. 315 (17.5) 225 (22.7) 11 (23.9) 78 (16.8) 1 (0.6) <0.01 
Median hospital stay (IQR) 36 (21-53) 36 (21-51) 36 (22-48) 39 (18–54) 34 (23-53) .92 
In-hospital mortality (%) 521 (28.9) 301 (27.9) 8 (15.4) 184 (36.5) 28 (16.6) <0.01 
One-yearmortality (%) 116 (9.1) 81 (10.4) 1 (2.27) 29 (9.0) 5 (3.5) .05 
 
BC, blood cultures;BSI, Blood stream infection; CNS, coagulase-negative staphylococci; TEE, transesophageal echocardiogram; 
IE, infective endocarditis; IQR, interquartile range; MRSA, methicillin-resistant S. aureus
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Non-IVDU patients with native valve IE 
Most of the patients in our series (59.8%) were non-IVDU, which is 
therefore the most heterogeneous group. Although it is difficult to 
identify one characteristic that stands out, these patients presented less 
frequently history of heart failure (23.6%) or renal failure (23.9%). Most 
cases were community-acquired, and Streptococcus spp. was the most 
common pathogen involved. 
 
Native valve IE in IVDU accounted for the smallest group of our series.  
Native valve IE affected significantly younger patients with fewer 
comorbid conditions, except in the case of HIV infection (44.2%). 
Acquisition was nosocomial in only 1.9% of the cases and, interestingly, 
half of these patients had left-sided IE. A clinical presentation was more 
evident in this population including splinter hemorrhages (16%) and 
splenomegaly (31.4%). S. aureus predominated as the etiological 
microorganism (53.8%), and embolisms were frequent (60.0%). Outcome 
was clearly better in this group. 
 
Prosthetic valve IE. 
The highest in-hospital mortality was recorded in patients with 
prosthetic valve IE (36.5% p<0.01); however, it is of even greater 
concern that infection was nosocomial in 39.7% of these patients. 
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Coagulase-negative staphylococci accounted for 28.0% of the cases. 
Accordingly, intra-cardiac complications were significantly more 
frequent (33.9%). 
Cardiac device IE.Patients with heart devices were older, with highest 
comorbidity index and a great part (62%) were nosocomial or health 
care related.    The device involved was surgically removed in 65.1% of 
the cases. 
 
Short-term and long-term risk factors for mortality 
Table 3 shows a comparison of the patients who survived (71.1%) and 
those who died (28.9%) during admission; table 4 shows the 
independent risk factors associated with a higher risk of in-hospital 
death. Independent mortality risk factors could be grouped as: 
epidemiological characteristics of the patient, endocarditis etiology 
(Staphylococcus spp [OR, 2.34], fungi [OR, 3.12]) and complications 
(intra-cardiac complication [OR, 1.67], heart failure [OR, 2.97], and 
septic shock [OR, 5.18]). 
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Table 3.Risk factors for in-hospital mortality 
 Alive 
N=1283 
Dead 
N=521 
p 
Median age (IQR) 67.6 (53.7 – 76) 73 (62.9 – 78.9) <0.01 
Male 907 (70.7) 321 (61.8) <0.01 
Underlying condition 
Heart failure 
Previous cardiac surgery 
Diabetes mellitus 
Mild renal insufficiency 
Severerenal insufficiency 
Atrial fibrillation 
Lung disease 
Neoplasm 
HIV infection 
Previous IE 
 
326 (25.6) 
411 (32.4) 
294 (22.9) 
117 (9.2) 
163 (12.8) 
288 (22.8) 
209 (16.7) 
199 (15.5) 
29 (2.3) 
101 (7.9) 
 
205 (40.0) 
209 (40.4) 
177 (34.1) 
71 (13.8) 
117 (22.7) 
169 (33.2) 
103 (20.4) 
91 (17.5) 
10 (2.0) 
25 (4.8) 
 
<0.01 
.001 
<0.01 
.004 
<0.01 
<0.01 
.067 
.296 
.675 
.020 
Charlson-age comorbidity (SD) 4.1 (2.5) 5.4 (2.5) <0.01 
Transferred from other hospital 
Symptoms before admission (median days [IQR]) 
340 (26.5) 
6 (1 – 18) 
139 (26.7) 
2 (0 – 8) 
.938 
<0.01 
Affected valve 
Aortic 
Mitral 
Tricuspid 
Pulmonary 
 
594 (46.3) 
541 (42.2) 
80 (6.2) 
22 (1.7) 
 
258 (49.5) 
267 (51.2) 
19 (3.6) 
7 (1.3) 
 
 
.214 
<0.01 
.029 
.570 
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 Alive 
N=1283 
Dead 
N=521 
p 
Proven endocarditis 
Possible endocarditis 
1054 (82.3) 
227 (17.7) 
444 (85.9) 
73 (14.1) 
.064 
.064 
Etiology (%) 
S. aureus 
Methicillin-resistantStaphylococcus aureus 
Coagulase-negativestaphylococci 
Streptococcusspp. 
Enterococcus spp. 
OtherGram-positivemicroorganisms 
Gram-negativemicroorganisms 
Fungi 
Negative blood cultures 
 
237 (18.5) 
34 (2.7) 
201 (15.7) 
371 (28.9) 
177 (13.8) 
19 (1.5) 
76 (5.9) 
25 (2.0) 
110 (8.6) 
 
189 (36.5) 
32 (6.1) 
101 (19.4) 
69 (13.2) 
53 (10.2) 
7 (1.3) 
17 (3.3) 
19 (3.6) 
54 (10.4) 
 
<0.01 
<0.01 
.058 
<0.01 
.037 
.824 
.021 
.034 
.230 
Vegetation 
Intracardiac complication 
Transesophageal echocardiogram 
887 (69.1) 
310 (24.3) 
1004 (78.3) 
397 (76.5) 
191 (37.0) 
375 (71.9) 
.002 
<0.01 
<0.01 
Persistent bacteremia 69 (5.5) 82 (16.7) <0.01 
Heart surgery 
     Indicated 
     Operated on 
 
728 (56.8) 
598 (46.7) 
 
424 (81.4) 
199 (38.2) 
 
<0.01 
.001 
Reasons for surgery (%) 
    Cardiac insufficiency 
    Early prosthetic IE 
    Late prosthetic IE 
Valvular insufficiency 
 
254 (21.5) 
47 (4.0) 
46 (3.9) 
245 (20.8) 
 
119 (24.5) 
31 (6.4) 
32 (6.6) 
70 (14.4) 
 
.185 
.036 
.019 
.003 
Median hospital stay (IQR) 41 (27 – 55) 23 (11 – 42) <0.01 
BC,blood cultures; TEE, transesophageal echocardiogram; IE,infective endocarditis; IQR, interquartile range; SD,standard 
deviation. 
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Table 4. Independent risk factors for in-hospital mortality 
Factor OR 95% CI p 
Age 1.02 1.01 – 1.03 <0.01 
Immunosuppressive 
therapy 
2.61 1.68 – 4.04 <0.01 
Previous heart surgery 
(previous to the episode of 
IE) 
1.53 1.17 – 2.00 .002 
CNS event 2.47 1.91 – 3.19 <0.01 
Atrial fibrillation 1.45 1.09 – 1.93 .011 
Staphylococcus aureus 2.34 1.75 – 3.12 <0.01 
Fungi 3.12 1.50 – 6.49 .002 
Intra-cardiac complication 1.67 1.30 – 2.14 <0.01 
Heart failure 2.97 2.30 – 3.83 <0.01 
Septic shock 5.18 3.62 – 7.40 <0.01 
 
Overall, 1283 patients survived hospital admission, and one-year 
follow-up was available in 1035 (80.6%). Independent risk factors for 
one-year mortality are shown in table 5 and include increasing age (OR, 
1.02), neoplasm (OR, 2.46), renal insufficiency (OR, 1.59), and heart 
failure (OR, 4.42). Surgery was independently associated with a 
decreased risk of one-year mortality (OR, 0.44) and was the only factor 
amenable of intervention.  
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Table 5. Independent risk factors for one-year mortality  
Factor OR 95% CI p 
Age 1.02 1.00 - 1.03 .005 
Neoplasm 2.46 1.57 – 3.86 <0.01 
Surgery 0.44 0.286 - 0.694 <0.01 
Renal insufficiency 1.59 1.04 – 2.42 .030 
Heart failure 4.42 1.06 - 18.40 .041 
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II. Epidemiological, microbiological, and clinical characteristics of 
Enterococcal IE. 
 
Our design includes 2 studies. In the first one, we aimed to assess 
the frequency of enterococcal IE by analyzing a prospective cohort 
including all patients with E-BSI. In the second, we performed a 
case-control study comparing patients with and without 
enterococcal IE. Both studies were performed in a 1550-bed tertiary 
center attending a population of 715,000 habitants. 
 
Prospective cohort study: The study sample comprised all cases of 
E-BSI diagnosed in our institution from September 2003 to October 
2012. During this period, we identified 2 phases that differed with 
respect to the diagnosis of IE. From 2003 to 2007, patients with E-
BSI were managed by the attending physician who requested 
consultation with the infectious diseases department or the 
laboratory of echocardiography [3] according to his/her own criteria 
(Period A). From 2008-2012 (Period B), a physician from the 
infectious diseases department visited the patients with E-BSI and 
promoted the systematic use of echocardiography. We recommended 
the systematic performance of TEE in most patients, provided the 
patient consented to and the attending physician agreed with the 
indication. The need for TEE in patients referred for transthoracic 
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echocardiography (TTE) was occasionally indicated by the 
cardiologist. Accordingly, in some patients, only TTE was performed, 
in some TTE and TEE, and in others neither of the 2 techniques. 
From September 2003 onward, clinical data on all patients with 
enterococcal IE were collected prospectively as part of a pre-
established protocol. 
 
Case-control study: We designed a case-control study to identify a 
subgroup of patients at very low risk of enterococcal IE in whom 
systematic TEE could safely be deemed unnecessary. All patients 
fulfilling the modified Duke criteria [12] for IE were considered 
cases, and patients with E-BSI and a TEE result that ruled out IE 
were considered controls. Control patients were randomly selected 
from among patients with E-BSI and a negative TEE result and no 
criteria for IE according to the modified Duke criteria [12].Both 
groups were independently selected from the period in which they 
presented. 
 
To evaluate the possibility of misdiagnosed IE we reviewed the 
clinical records of a randomly selected significant sample 
(176/1127) of patients with enterococcal bacteremia that did not 
undergo TEE. We analyzed main clinical characteristics and 
duration of therapy. The selected parameters were: previous valve 
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disease; origin of bacteremia; number of positive blood cultures; 
recurrence of bacteremia; clinical, microbiological, and/or 
radiological findings suggestive of septic embolism; NOVA score; 
treatment and outcome during admission and follow-up. Patients 
were followed up for a mean of 653 days after discharge.     
 
Statistical analysis 
In the descriptive study, qualitative variables are presented as 
percentages with their confidence interval (CI) and quantitative 
variables as the mean and CI and/or median with the interquartile 
range, depending on the distribution. Clinical and microbiological 
variables were studied to obtain a predictive model for enterococcal 
endocarditis. Differences between groups were analysed using the t 
test, median test, X2 test, or Fisher exact test, depending on the 
characteristics of the variables and their distribution between 
groups. The sensitivity of TTE/TEE was compared with a McNemar 
test for pair samples. The evolution of the variables during the study 
period was assessed using the autoregressive integrated moving 
average test. 
In order to develop a reliable algorithm that made it possible to rule 
out the need for TEE, we designed a strategy based on 
bootstrapping. Given that the same case-control dataset was used 
for development of the model, testing, assessment of goodness of fit, 
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and establishing threshold values, we implemented bootstrapping 
techniques to avoid overfitting. The association between individual 
predictors and the risk of IE was assessed using binary multivariate 
logistic regression including variables selected from the exploratory 
univariate analysis. Final variables in the model were selected using 
a backward stepwise approach based on Alkaike’s information 
criterion [16] and clinical judgment. This logistic regression model 
was validated by 2 runs of 2000 bootstrap replications [17] with IE 
prevalence values of 50% (as in the case-control group) and 4.3% (as 
in the prospective cohort). After validation, we developed a 
quantitative score for the risk of endocarditis by rounding the 
estimated odds ratio (OR) values of the model. This synthetic 
univariate prediction score was tested in a second logistic regression 
model and again validated by 2 bootstrapp runs, as described 
above. Additionally, the logistic regression model was calibrated by 
plotting predicted versus observed probabilities. Finally, bootstrap-
based 95% confidence intervals were obtained for sensitivity and 
specificity and overlaid on the ROC plot [18, 19]. A conservative cut-
off for the predictive score was based on the maximization of 
sensitivity, as recommended for screening methods. Data were 
analyzed using SPSS, version 18.0 (SPSS Inc, Chicago, Illinois, USA) 
and R[20]. 
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Incidence of enterococcal endocarditis 
During the study period (2003-2012), we detected 1515 episodes of 
E-BSI. The annual distribution is shown in table 6. Of these, 679 
(2.1 episodes/1000 admissions) occurred in period A (2003-2007) 
and 836 (3.1 episodes/1000 admissions) in period B (2008-2012). 
This increase was statistically significant (p<0.001). The annual 
increase in E-BSI was 0.167 episodes/1000 admissions (95%CI, 
0.100-0.234; P<0.001). Overall, 388 patients underwent TEE after 
the episode of E-BSI: 100 during period A (14.7% of all E-BSI) and 
288 during period B (34.4% of all E-BSI). 
 
Table 6. Enterococcal bloodstream infections (E-BSI) and endocarditis (EE) 
during the study period. 
Year 
E-BSI 
episodes 
E-BSI/1,000 
admissions 
EE 
episodes 
EE/E-BSI 
(%) 
EE / 1000 
admissions 
2003 109 2.0 2 1.8% 0.04 
2004 114 1.9 8 7.0% 0.13 
2005 129 2.1 3 2.3% 0.05 
2006 149 2.3 5 3.3% 0.08 
2007 178 2.6 8 4.4% 0.12 
2008 177 3.0 5 2.8% 0.12 
2009 170 3.2 9 5.2% 0.15 
2010 149 2.7 3 2.0% 0.05 
2011 181 3.4 14 7.7% 0.26 
2012 159 3.2 8 5.0% 0.14 
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Enterococcal IE was detected in 65 patients, who accounted for 4.29% 
of all patients with E-BSI (3.76% in period A and 4.54% in period B). 
The increase in the annual incidence of enterococcal IE was 0.012 
episodes/1000 admissions (95%CI, 0.004-0.020; P=0.004). IE was 
diagnosed in 16.7% of patients who underwent TTE and 35.5% of the 
patients who underwent TEE. Of all the episodes of enterococcal IE, 
only 18 cases (27.7%) were detected by TTE; the remaining 47 (72.3%) 
were demonstrated only after TEE. Sensitivity of TTE and TEE for the 
diagnosis of enterococcal IE was 32% vs 95% (p<0.01). 
Comparison of E-BSI patients with and without endocarditis 
In order to identify characteristics that could help to identify IE among 
patients with E-BSI, the 65 cases were compared with the 65 controls. 
The epidemiological, microbiological, and clinical characteristics of both 
groups are shown in table 7. No differences were detected in age or sex, 
but patients with IE more frequently presented a history of stroke 
(27.7% vs 13.8%, p=0.05), immunosuppressive therapy (24.2% vs 
10.8%, p=0.03), previous heart valve disease (63.0% vs 29.2%, p<0.01), 
and previous heart valve surgery (44.6% vs 24.6%, p=0.03). Malignancy, 
however, was more frequent in controls (23% vs 41.5%, p=0.02). 
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Table 7. Epidemiological, clinical and microbiological characteristics of 
patients with and without enterococcal endocarditis. 
 Endocarditis (%) No Endocarditis (%) p 
Mean age (SD) 71.2 (11.3) 70.3 (13.6) 0.7 
Females 
Males 
18 (27.7) 
47 (72.3) 
23 (35.4) 
42 (64.6) 
0.34 
Underlying disease    
    Congestive heart failure 
 Yes 
No 
 
27(41.5) 
38 (58.5) 
 
19 (29.2) 
46 (70.8) 
0.09 
Stroke 
Yes 
No 
 
18 (27.7) 
47 (72.3) 
 
9 (13.8) 
56 (86.2) 
0.05 
Transplant 
Yes 
No 
 
6 (9.2) 
59 (90.8) 
 
7 (10.8) 
58 (89.2) 
0.77 
   Immunosuppression  
Yes 
No 
 
15 (23) 
50 (76.9) 
 
7 (10.8) 
58 (89.2) 
0.03 
    Neoplasm 
Yes 
No 
 
14 (21.5) 
51 (78.5) 
 
27 (41.5) 
38 (58.5) 
0.02 
    Renal failure 
Yes 
No 
 
23 (35.4) 
42 (64.6) 
 
21 (32.3) 
44 (67.7) 
0.41 
    Previous endocarditis  
Yes 
No 
 
8 (12.3) 
57 (87.7 ) 
 
4 (6.2) 
61 (93.8 ) 
0.17 
    Heart valve disease 
Yes 
No 
 
41(63.1) 
24 (36.9) 
 
19 (29.2) 
46 (70.8 ) 
<0.01 
Prostheticvalve 
Yes 
No 
 
31(47.7) 
34 (52.3) 
 
17 (26.2) 
48 (73.8) 
0.18 
    Native valve disease 
Yes 
No 
 
10 (15.4) 
55 (84.6) 
 
2 (3.1) 
63 (96.9 ) 
0.07 
    Previous cardiac valve surgery 
Yes 
No 
 
25 (38.5) 
40 (61.5) 
 
16 (24.6) 
49 (75.4) 
0.03 
Mean Charlsonindex (SD) 5.47 (2.3) 6.5 (2.9) 0.02 
Clinical presentation    
Fever 
Yes 
No 
 
59 (90.7) 
6 (9.2) 
 
58 (89.2) 
7 (10.8) 
0.36 
    Heart murmur 
Yes 
No 
 
37 (56.9) 
28 (43.1) 
 
19 (29.2) 
46 (70.8) 
<0.01 
Etiology      
   E. faecalis 
Yes 
No 
 
 
56 (86.2) 
9 (13.8) 
 
38 (58.5) 
27 (41.5) 
<0.01 
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   E. faecium 
Yes 
No 
 
7 (10.8) 
58 (89.2) 
 
24 (36.9) 
41 (63.1) 
<0.01 
Enterococcus. spp 
Yes 
No 
 
2 (3.1) 
63 (96.9) 
 
3 (4.6) 
62 (95.4) 
0.65 
Continuousbacteremia 
Yes 
No 
 
61 (93.8) 
4 (6.2) 
 
45 (69.2) 
20 (30.8) 
<0.01 
Site of acquisition     
    Community 
Yes 
No 
 
28 (43.1) 
37 (56.9) 
 
13 (20) 
52 (80) 
<0.01 
Nosocomial 
Yes 
No 
 
30 (46.2) 
35 (53.8) 
 
45 (69.2) 
20 (30.8) 
0.01 
    Health care–associated 
Yes 
No 
 
7 (10.8) 
58 (89.2) 
 
7 (10.8) 
58 (89.2) 
0.03 
Source of BSI    
    Gastrointestinal 
Yes 
No 
 
9 (13.8) 
56 (86.2) 
 
31 (47.7) 
34 (52.3) 
<0.01 
Unknown* 
Yes 
No 
 
25 (38.5) 
40 (61.5) 
 
7 (10.8) 
58 (89.2) 
<0.01 
* Overral 16/32 (50%) had colonoscopy (4/7 patients without endocarditis an 12/25 
patients with endocarditis). 
 
Episodes of IE were caused mainly by E. faecalis (86.2% vs 58.5%, 
p<0.01). In addition, they were associated with continuous bacteremia 
(93.8% vs 69.2%, p<0.01), community acquisition (43.1% vs 20%, 
p<0.01), and unknown source of infection (38.4% vs 10.7%, p<0.01). In 
the control group, however, E-BSI was mainly nosocomial (69.2% vs 
46.2%, p=0.01) and had a gastrointestinal origin (48.4% vs 13.8%, 
p<0.01).  
As for outcome, patients with IE presented more complications (Table 8) 
and had significantly higher mortality (38.4% vs 15.4%, p<0.01). 
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Table 8.Outcome of patients with and without endocarditis. 
 
 
 
Endocarditis 
N=65 (%) 
No Endocarditis 
N=65 (%) 
p 
Complications    
Cardiacfailure 23(35.9) 6 (9.2) <0.01 
Persistent BSI 13 (21.7) 9 (13.8) 0.09 
CNS vascular event 5 (7.9) 0 0.02 
Other than CNS embolic event 10 (15.9) 2 (3.1) 0.007 
Treatment    
Empiricadequatetreatment 54 (96.4) 13 (20.0) <0.01 
Mean days of overall treatment 
(SD) 
34 (17.1) 15 (8.2) <0.01 
Death 25 (38.4) 10 (15.4) <0.01 
Mean days of hospital stay (SD) 47.3 (29.7) 36.2 (33.0) 0.04 
BSI, bloodstream infection; CNS, central nervous system. 
 
 
Score for identifying bacteremic patients with a low risk of IE 
The multivariate analysis showed that enterococcal IE is 9-fold more 
probable in patients with positive blood cultures in all of 3 blood 
cultures or the majority of more than 3 blood cultures (OR, 9.9; 95%CI 
2.2-40.6). Other factors independently associated with enterococcal IE 
were a history of heart valve disease (OR, 3.7; 95%CI, 1.6-8.7) and an 
unknown source of bacteremia (OR, 7.7; 95%CI, 2.5-23.8). We 
developed a score using the variables selected in the multivariate model 
by including those that improved sensitivity and specificity for 
predicting enterococcal IE. This model validated both very well using 
bootstrap resampling based on prevalence values of 50% (slope 
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shrinkage factor for the agreement between the training and test 
samples, 0.88; maximum absolute error in predicted probability, 0.03) 
and 4.3% (slope shrinkage factor=0.90; maximum error=0.02). The ORs 
of these models were used to obtain representative weights by rounding 
to develop a synthetic score on a scale of 0 to 12 for the risk of IE in 
patients with E-BSI. The score, which we called the NOVA score, was 
based on the following variables: number of positive blood cultures (N) 
suggestive of continuous bacteremia (3/3 blood cultures or the majority 
if more than 3), 5 points;, 5 points; unknown origin of bacteremia (O), 4 
points; prior valve disease (V), 2 points; and auscultation of a heart 
murmur (A), 1 point. The area under the ROC curve for the NOVA score 
was 0.829 (95%CI, 0.758-0.901). Again, this model was accurately 
validated by bootstrapping (slope shrinkage factor=0.99 and 1; 
maximum error=0.003 and 0.002, for the resampling runs each 
stratified by the IE prevalence values of 50% and 4.3%, 
respectively).The best binary cut-off value for ruling out IE without the 
need for TEE was established at a NOVA score <4 points (Figure 1).  
Figure 1. Best binary cut-off value for ruling out IE without the need for TEE. 
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Using this cut-off, the model calibration curve excluded the risk of false 
negatives (Figure 2). The probability of enterococcal IE with different 
scores is as follows: 5 points, 23.3%; 6 points, 45.5%; 7 points, 82.4%; 
8 points, 66.7%; 9 points, 60.0%; 10 points, 100%; 11 points, 83.3%; 
12 points, 80%. 
Figure 2. Model calibration curve 
 
None of the 65 patients with enterococcal IE had a NOVA score lower 
than 4 in our series (Figure 3). According to this model, the percentage 
of patients with E-BSI who would not require echocardiography (score 
<4 points) ranged from 14.6% in a setting with a prevalence of 
endocarditis of 50%, such as our case-control study, to 27.7% in a 
setting with a 5% prevalence of endocarditis.  
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Figure 3. Distribution of Enterococcal IE and E-BSI, according to the NOVA score. 
 
Therefore, according to our model, in populations with a low prevalence 
(5%) and high prevalence (20%) of IE, the proportion of patients with E-
BSI in whom TEE may not be necessary is 27.7% and 23.4%, 
respectively (Figure 4). 
 
Figure 4. Proportion of patients with E-BSI in whom TEE may not be necessary 
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Analysis of a sample of E-BSI patients who did not undergo 
echocardiography 
After a careful record review, only 3/176 patients (1.70%) without TEE 
could have had IE according to the selected clinical criteria. All 3 had 
been treated for at least 4 weeks. Regarding length of treatment with 
appropriate regimens, only 12/176 patients received more than 2 weeks 
of therapy (3 with bacteremia of unknown origin, 6 with cholangitis, 1 
with osteomyelitis, 1 with infected knee prosthesis, and 1 with fecal 
peritonitis). As for occurrence of embolic episodes, only 2 patients 
presented with clinical, microbiological, and/or radiological evidence of 
septic embolism: a 79-year-old patient with multiple bilateral 
pulmonary consolidations who refused to undergo TEE and a 92-year-
old man with severe Alzheimer disease and L4-S1 osteomyelitis whose 
family refused TEE. Both patients had been treated at least 4 weeks 
before discharge. Finally, we classified the 176 patients according to the 
NOVA score. Overall, 106 had a score <4 points and were treated for a 
mean of 14 (SD 5.2) days. None of them presented clinical, 
microbiological, or radiological signs of embolism or IE during follow-up. 
Seventy patients had a NOVA score ≥4points. Three of these patients 
were thought to have had IE and 2 presented with an embolic 
complication, as previously mentioned. They had all been treated for 
more than 2 weeks. We cannot rule out the possibility of endocarditis in 
patients who died early after E-BSI. 
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External validation of the predictive NOVA score for infective 
endocarditis among patients with enterococcal bloodstream infection 
Setting 
S’ OrsolaMalipighi Hospital in Bologna is a 1,420-bed tertiary teaching 
institution in Northern Italy, with approximately 72,000 hospital 
admissions per year. Institutional Ethics Committee approved the 
study. 
To validate the NOVA score we performed a retrospective study of all the 
patients with E-BSI studied with echocardiography for ruling out IE. 
Using the records of our Laboratory of Microbiology all the patients with 
E-BSI, hospitalized at our hospital from January 2011 to December 
2013, were identified. The patient charts were reviewed to assess if IE 
had been ruled out by echocardiography. Data of all the patients with 
echocardiography were collected in a case report form including the 
parameters of the NOVA score (Number of positive blood cultures, 
Origin of the bacteremia, previous Valve disease, and Auscultation of 
heart murmur). Clinical data up to 1 year after E-BSI were reviewed as 
follow-up.  
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The NOVA score was calculated for every enrolled patient considering 
the followings parameter and their values: number of blood cultures 
(3/3 or the majority if more than 3 = 5 points); origin of BSI (unknown= 
4 points); prior valve disease (2 points); auscultation of heart murmurs 
(1 point).  
Statistical analysis 
Categorical variables were presented as absolute numbers and their 
relative frequencies. Quantitative variables were presented as mean and 
standard deviation (SD) if normally distributed or as median and 
interquartile range (IQR) if non-normally distributed.  
The discriminatory power for the NOVA score was evaluated by the area 
under the receiver operating characteristic (ROC) curve. The Youden’s J 
statistics was used to establish the optimal cutoff for discriminating 
patients at low and high risk for IE in our hospital. Sensibility, 
speciﬁcity, positive and negative predictive values were calculated 
according to the prevalence of enterococcal EI. 
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Results 
During the study period, 449 patients with E-BSI were identified. Of 
them, 100 patients were studied with echocardiography: trans-thoracic 
in 83, trans-esophageal in 5, and both in 12 patients; and analyzed for 
this study. 
Mean age was 64.7 (±15.8) years, 58% were male. The mean Charlson 
index was 4.3 (±1.8). E-BSI was classified as community acquired, 
health-care associated and hospital acquired in 19%, 23% and 58% of 
cases, respectively. 
Etiological distribution of E-BSI was as follows: E. faecalis 61%, 
E.faecium 30%, and other Enterococcus spp. 9%.  
Enterococcal IE was diagnosed in 24 patients, with a prevalence of 5.3% 
among all patients with E-BSI and 24% among those with an 
echocardiography.  
Comparison of patients with and without IE is shown in Table 9. 
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Table 9. Patients with enterococcal bloodstream infection studied with 
echocardiography: comparison of patients with and without infective endocarditis    
 Total, n=100 
(100%) 
Patients without 
IE,  N=76 
(76%) 
PatientswithIE, 
N=24 
(24%) 
P 
Demographic data      
Age (years) [mean (±SD)] 57 (±12) 64 (±16) 64 (±12) 0.9 
   Sex, male 56 (56) 40 (52) 16 (66) 0.2 
Comorbidities     
Charlsonindex [mean (±SD)]  4.6 (± 2) 4.7 (±2) 4.3 (±1.8) 0.46 
Chronickidneydisease 14 (14) 5 (18) 14 (70) 0.02 
   Neoplasia 34 (34) 30 (39) 4 (16) 0.49 
Site of BSI acquisition     
Hospitalacquired 58 (58) 51 (67) 7 (29) 0.002 
Healthcareassociated 23 (23) 11 (14) 12 (50) 0.001 
Communityacquired 19 (19) 14 (18) 5 (20) 0.7 
Source of BSI     
Unknown 47 (47) 23 (30.3) 24 (100) <0.001 
   CVC 17 (17) 17 (22.3) 0 NA 
Gastro-intestinal 14 (14) 14 (18.4) 0 NA 
Biliary 10 (10) 10 (13.1) 0 NA 
Urinary 8 (8) 8 (10.5) 0 NA 
Skin and softtissues 4 (4) 4 (5.2) 0 NA 
Diagnosticalprocedures     
   TTE 95 (95) 75 (98) 20 (83) 0.01 
   TEE  17 (17) 3 (3) 15 (58) <0.001 
  FDG-PET 20 (20) 8 (10) 12 (50) <0.001 
NOVA score  
   Number of positive blood cultures 
[median (IQR)] 
Origin of BSI (unknown) 
   Valve disease (previous) 
   Auscultation of heart murmur     
 
3 (2-3) 
 
47 (47) 
31 (31) 
14 (14) 
 
2 (2-3) 
 
23 (30) 
16 (21) 
5 (6) 
 
3 (3-4) 
 
24 (100) 
15 (62) 
9 (37) 
 
<0.001 
 
<0.001 
<0.001 
0.001 
Endocarditis     
    Mitral valve 17 (17) 0 17 (70) NA 
    Aorticvalve 14 (14) 0 14 (58) NA 
Tricuspidvalve 2 (2) 0 2 (8) NA 
Pacemaker associated 2 (2) 0 2 (8) NA 
Abbreviations: BSI bloodstream infection; CVC central venous catheter; FDG-PET fluorodeoxyglucose-positron emission tomography; IQR 
interquartile range; NA not applicable; SD  standard deviation; TTE transthoracic echocardiography; TEE transesophageal echocardiography. 
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The ROC curve analysis suggested that the NOVA score could 
acceptably discriminate low versus high risk patients, with an area 
under the curve of 0.96 (95%CI 0.93-0.99, p<0.00) (Figure 5). The 
probabilities of enterococcal IE for the different thresholds of the NOVA 
score were: 0%, 0-5 points (63 patients); 12.5%, 6-8 points (8 patients); 
75%, 9-10 points (12 patients); and 82.3%, 11-12 points (17 patients) 
as reported. The optimal breakpoint in our cohort resulted to be >5. 
Considering a pre-test prevalence of endocarditis among patients with 
E-BSI of 5.3%, sensitivity, specificity, positive and negative predictive 
values for the cutoff >5 were: 100%, 83%, 23.5% and 100%, respectively 
(Table 10). None of the 63 patients with a score ≤5 showed signs or 
symptoms of IE during the 1-year follow-up.  
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Figure 5. a)Distribution ofpatients according with the NOVA score: Number of blood cultures (3/3 or the majority if more than 3 = 5 points); 
Origin of BSI (unknown= 4 points); prior valve disease (2 points); auscultation of heart murmurs (1 point). Dashed line indicate the established 
cut-off of >5. b) The discriminatory power of NOVA score in the validation cohort was assessed by the receiver operating characteristics (ROC) 
analysis which showed an area under the curve (AUC) of 0.96. Dashed line representstheidentity line.   
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Table 10. Accuracy of NOVA score according with stratified values  
Score value >0 >1 >2 >4 >5 >6 >7 >9 >10 >11 
True positive  24 24 24 24 24 23 23 17  14 6 
False positive  48 42 34 28 13 11 6 4 3 0 
False negative 0 0 0 0 0 1 1 7 10 18 
True negative 28 34 42 48 63 65 70 72 73 76 
SE (%) 100 100 100 100 100 95.8 95.8 70.8 58.33 25 
SP (%) 36.8 44.7 55.2 63.1 82.9 85.5 92.1 94.7 96.5 100 
PPV* (%) 7.6 8.6 10.5 12.4 23.5 25.8 38.9 41.2 58.3 100 
NPV (%) 100 100 100 100 100 99.7 99.7 98.4 96 96 
 *Positive predictive value was calculated for a prevalence of infective endocarditis of 
5%.  
SE sensitivity; SP specificity; PPV positive predictive value; NNV negative predictive value. 
Using the model, the percentage of patients with E-BSI who would not 
require echocardiography (score ≤5 points) was 63% and 78.7% for IE 
prevalence of 24% and 5%, respectively. 
Eleven of the 24 patients with IE developed at least one septic embolic 
event at level of central nervous system (n=3), spleen (n=3), spinal 
column (n=3), skin (n=1) and lung (n=1). The crude mortality rate of 
patient with IE was 25%. In 5 out of the 6 deceased patients the 
mortality cause was attributed to IE.  
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III. Systematic performance of new diagnostic imaging 
techniques in IE patients. 
We performed a prospective cohort study (IE patients with PET) 
involving matched controls in a 1500-bed tertiary hospital attending a 
population of 700,000 inhabitants. From January 2012 to July 2013, 
all patients with proven IE underwent PET-CT. The exclusion criteria 
for PET-CT were hemodynamic instability, pregnancy, surgery during 
the previous month, clinical intolerance to the test, and known active 
malignancy. Patients (cases) were matched by affected valve and 
etiology of definite IE with patients from our cohort who were diagnosed 
before the PET-CT study was initiated (controls).  
Our hospital protocol for detecting septic embolism in patients with IE 
includes systematic CT of the chest and abdomen or abdominal 
ultrasound and cranial CT or magnetic nuclear resonance imaging 
(MRI) if central nervous system symptoms are present. PET-CT was 
performed simultaneously with these conventional diagnostic 
techniques. 
Patient Preparation for PET-CT. Patients fasted for at least 6 hours 
before the PET-CT study (i.e. with respect to time of injection of 18F-
FDG).  If present, hyperglycemia was corrected according to our 
hospital protocol. PET was not performed if glucose levels were > 160 
mg/dl in non-diabetic patients or > 200 mg/dl in diabetic patients at 
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injection of 18F-FDG. The injection and uptake phase lasted 45 
minutes.    
According to our hospital protocol, diagnostic craneo-cervico-thoraco-
abdominal contrast-enhanced CT scan with intravenous contrast 
media (OptirayUltraject 300 mg/ml) was performed in all cases, except 
those with documented allergy, compromised renal function, or 
concomitant medication (metformin). The intravenous enhanced 
contrast was administrated when the patient was already laid on the 
hybrid PET-CT device and this methodology allowed us to avoid the 
time-lapse between explorations. Oral contrast (barium sulphate 5%, 
150 ml, Rovi) was administered in all cases in order to improve the 
evaluation of the alimentary tract, unless poor tolerance was observed 
or anticipated. A total of four MBq/Kg of 18F FDG (350-400 MBq) was 
administered intravenously 60 minutes before imaging with a 
subsequent rest period of 45 minutes. Afterwards, PET-CT images were 
acquired with a Siemens Biograph 6-4R truePoint w/true PET-CT 
device from the vertex to the mid-thigh.  Images were reconstructed in 
axial slices using iterative reconstruction true D.CT images. The 
attenuation correction was performed with PET / CT fusion in three 
planes and revised using LEONARDO software (e.soft PET / CT 
platinum work station. Siemens). All images were evaluated visually 
and quantitatively by a nuclear physician with PET-CT experience. In 
doubtful cases, the PET-CT scan was evaluated by at least 2 nuclear 
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medicine specialists. The CT part of the exam was evaluated 
independently by an expert radiologist. In the PET-CT scan, the 
presence or absence of abnormal accumulation of 18F-FDG, especially 
focal accumulation, was evaluated, as was its size and intensity. 
Qualitative and semi-quantitative values (maximum standardized 
uptake value [SUVmax] and mean standardize uptake value [mean 
SUV]) were recorded for each lesion. Any non-physiological focal uptake 
superior to that of healthy surrounding tissue (in the case of small 
lesions approximately <2 cm in size) or uptake superior to reference 
parenchymal uptake of the mediastinal blood pool or the liver in the 
case of larger lesions was considered suggestive of pathologically 
increased metabolic activity. Non-infectious incidental focal hyper-
metabolic lesions were classified as neoplasm or inflammation 
according to radiological, clinical and histological findings, 
independently of SUV values. Response was assessed by reviewing the 
images using the same colour scale range, and mean SUV liver uptake 
values were recorded for both examinations. Images were considered to 
be comparable in the case of an overlap of x2 SD of liver mean SUV. 
Both uncorrected and attenuation-corrected images were assessed in 
order to identify any artefacts caused by contrast agents, metal 
implants, and/or patient motion. 
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Definitions and Evaluation Criteria  
A true-positive PET-CT result was defined as an abnormal 18F-FDG 
uptake by any organ or tissue, confirmed as a pathological lesion with 
clinical, microbiological, and/or standard imaging findings. A false-
positive PET-CT result was defined as abnormal 18F-FDG uptake in 
the absence of clinical and/or microbiological findings, with negative 
standard imaging results and no relapse during follow-up. Non-
infectious incidental PET-CT findings were excluded from the efficacy 
analysis.  
Statistical analysis 
The analyses were performed using SPSS version 18.0 (SPSS Inc., 
Chicago, Illinois, USA). All tests were 2-sided. A p value <0.05 was 
considered significant. For the classification of the PET-CT results, we 
used a discrepant analysis (14), which is recommended for the 
evaluation of new highly sensitive imaging tests. 
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Characteristics of the patients 
During the study period there were 70 endocarditis episodes, but 23 
patients had to be excluded from the study. The reasons for exclusion 
were early surgery (8 cases), early death (5 cases), discharge (5 cases), 
admission to the intensive care unit (2 cases), active malignancy (2 
cases) and intolerance of the test (1 case). Among excluded patients, IE 
was caused by Staphylococcus aureus (9 cases), S. epidermidis (4 
cases), unknown (4 cases), Enterococcus faecalis (3 cases), 
Streptococcus viridans (2 cases), and S. pneumoniae (1 case). Overall 
mortality during the study period was 29%. 
The study population thus included 47 patients from the 70 sequential 
cases of IE (67.1%).The epidemiological and clinical characteristics of 
the study patients are shown in table 11. Mean age was 61.3 years 
(±19 SD) and 30 were male. Infection was caused by Gram-positive 
microorganisms in 33 cases (70.2%), Gram-negative microorganisms in 
4 (8.5%), anaerobes in 5 (10.6%), fungi in 2 (4.2%; Aspergillus 
fumigatus 1 and Candida parapsilosis 1), unknown microorganisms in2 
(4.2%) and polymicrobial in 1 (2.1%). IE was left-sided in 38 of 47 cases 
(80.8%), prosthetic valves and/or cardiac devices were affected in 
48.9% and 24 (51.4%) of the patients presented a native valve IE. 
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Table 11.Epidemiological and clinical characteristics of patients with infective 
endocarditis: assessment of the extension of infection using PET-CT (cases) or 
conventional imaging methods (controls). 
 Cases (n=47) Controls (n=94) p 
Epidemiology    
Mean age (SD) 61.3 (19) 64.6 (21) 0.34 
Sex   0.8 
     Male 30 (63.8%) 62 (65.9%)  
     Female 17 (36.2%) 32 (34.1%)  
Immunosuppression 6 (12.8%) 13 (13.8%) 0.62 
     HIV infection 0 3 0.21 
     Transplantation 2 5 0.78 
Charlson’s comorbidity index 4.09 (± 2.7) 5.05 (± 2.6) 0.13 
Previous prosthetic valve 15 (31.9%) 40 (42.5%) 0.22 
     Aortic 9 (19.1%) 31 (32.9%)  
     Mitral 6 (12.7%) 7 (7.4%)  
     Pulmonary 0 2 (2.1%)  
Cardiac device 11 (28.5%) 21 (12.85%) 0.88 
      Pacemaker 8 (17.0%) 18 (19.1%)  
      Defibrillator 3 (6.4%) 3 (3.2%)  
Intravascular device 10 (21.2%) 7 (7.4%) 0.01 
   Central vein catheter 8 (17.0%) 6 (6.4%)  
   Other  prosthetic material 2 (4.2%) 1(1.0%)  
IE Episode    
Etiology    0.13 
     Gram-positive 33 (70.2%) * 70 (74.5%)  
     Gram-negative 4 (8.5%) ** 7 (7.4%)  
     Anaerobes 5 (10.6%)*** 1 (1%)  
     Fungi 2 (4.2%) 4 (4.2%)  
     Unknown 2 (4.2%) 10 (10.6%)  
Polymicrobial 1 (2.1%) 2 (2.1%)  
Anatomic distribution of IE    
     Prosthetic IE 15(48.6%) 40 (45.7%) 0.22 
          Aortic 8 20  
          Mitral 7 19  
     Native IE 24 (51.4%) 50 (54.3%) 0.81 
          Aortic 12 19  
          Mitral 11 25  
          Tricuspid 1 6  
     Cardiac device 8 (17.0%) 4 (4.2%)  
Outcome    
Treatment-related outcomes    
Days of treatment 43 days (IQR 34-53) 34 days (IQR 17-42) 0.1 
Time to effective treatment 3.67 days (+/- 7.8) 13.1 days (+/- 43) 0.15 
     Persistent BSI  3 (6.4%) 16 (17.0%) 0.08 
     Valve surgery replacement 30 (63.8%) 39 (41.5%) 0.01 
Clinical Outcome    
    Hospital stay 39 days (IQR 23-56) 29 days (IQR 17-54) 0.82 
    Infectious complications 27 (57.4%) 17 (18%) 0.0001 
    Readmission 5 (10.6%) 7 (7.4%) 0.5 
    Relapse 2 (4.2%) 9 (9.6%) 0.26 
IE, infective endocarditis.* E. faecalis, 11; S. aureus, 5; S. viridans, 4; S. gallolyticus, 3; S. epidermidis, 2; S. 
anginosus, 2; S. lugdunensis,  1; S. gordonii, 1; S. pneumoniae, 1; group C Streptococcus, 1; and A. defectiva, 
1. group G Streptococcus 1.**P. aeruginosa, 3; H. aphrophillus, 1.  ***A. actinomycetemcomitans, 1; B. 
thetaiotaomicron, 1; C. perfringens, 1; L. paracasei, 1; and P. acnes, 1. IQR:  interquartile range; BSI: 
bloodstream infection. 
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Median length of treatment was 43 days (IQR 34-53 days). Thirty 
patients (63.8%) underwent valve replacement. The 2 study patients 
who died were a heart recipient with A. fumigatus IE and a massive 
pulmonary embolism and a patient with S. epidermidis IE who 
presented septic shock. Finally, 1 patient with very extensive 
Clostridium perfringens IE is on the waiting list for heart 
transplantation. 
PET-CT Results 
PET/CT showed at least 1 lesion in 35 patients (74.5%). The 46 affected 
sites were as follows: lung, 10 (21.7%); bone, 7 (15.2%); sigmoid, 
rectum, and anus, 8 (17.4%); soft tissue 4 (8.7%) spleen, 3 (6.5%); brain 
and prosthetic valve, 4 each (17.4%); and extra-cardiac Fontan tube, 
aortic homograft, pulmonary valve graft, intravascular prosthetic 
material, right atrium and diaphragm (1 each).The classification of PET-
CT results according to our 
definitions is shown in table 12. Five 
patients (10.6%) had a non-infectious 
PET-CT finding (lung cancer, colonic 
adenocarcinoma, lymphocytic 
interstitial pneumonia, diverticulosis 
and solitary lung nodule).  A male patient with an aortic graft prosthetic 
material infectio 
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None of thefindings were identified by the conventional radiological 
extension study. These incidental findings were excluded from the 
efficacy analysis. 
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Table 12: Description of the 47 patients with IE in whom 18 FDG PET/CT was performed.  
Age/ 
Sex 
Microorganism PET-CT uptake sites Signs or 
symptoms 
Initial imaging 
technique 
Classification Treatment implication 
73/F P. aeruginosa Spondylodiscitis D12. Perm-cath. 
Pulmonary septic embolisms 
No Negative Very significant 
True positive* 
Therapy prolonged. Perm-cath 
withdrawn 
68/M C. perfringens Rectum and anus abscess No Negative Very significant 
True positive * 
Therapy prolonged. Origin of the IE 
identified 
68/M S. viridans Spondylodiscitis, Rectum and 
sigmoid 
Yes Negative Very significant 
True positive* 
Therapy prolonged and colonoscopy 
performed to rule out malignancy 
75/M E. faecalis Spondylodiscitis L1-L2 Yes Negative Very significant 
True positive* 
Therapy prolonged 
5/F Group C Streptococccus Extracardiacfontan tube No Negative Very significant 
True positive* 
Therapy prolonged 
81/M A. defectiva Spondylodiscitis L1-L2, L4-L5 Yes Negative Very significant 
True positive* 
Therapy prolonged 
83/M E. faecalis Spondylodiscitis L1 L2 L3 Yes Negative Very significant 
True positive* 
Therapy prolonged 
22/M L. paracasei Spleen embolism No Negative Very significant 
True positive* 
Therapy prolonged 
94/M C. parapsilosis Pulmonary septic embolisms No  Negative Very significant  
True positive* 
Therapy prolonged 
80/M Unknown Aortic graft prosthetic material  No Negative Very significant 
True positive* 
Therapy prolonged 
50/F S. aureus Pulmonary valve after tricuspid 
valve replacement 
No Negative Very significant 
True positive* 
Closer TEE  follow-up 
79/M S. epidermidis Soft tissue around pacemaker No Negative Very significant 
True positive* 
Relapsing BSI and septic shock 
2/F P. aeruginosa Pulmonary valve graft, and 
pulmonary septic embolisms 
Yes Negative Very significant 
True positive* 
Surgical removal of valve graft and 
therapy prolonged 
35/M S. aureus Brain and pulmonary embolisms Yes Negative Very significant 
True positive* 
Therapy prolonged 
68/M S. aureus Aortic homograft No Negative Very significant 
True positive* 
Aortic valve replacement 
33/M S. lugdunensis Pulmonary embolisms  No Positive True positive Therapy prolonged  
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50/M B. thetaiotaomicron Spleen embolism No Positive True positive Therapy prolonged 
54/F A. fumigatus Pulmonary embolism Yes Positive True positive Therapy prolonged 
78/F S. gallolyticus Pleural effusion Yes Positive True positive Completed IE treatment 
72/M H. aphrophillus Brain embolism Yes Positive True positive Therapy prolonged 
70/M E. faecalis Spleen abscess No Positive True positive Therapy prolonged 
87/F S. viridans 
 
Aortic prosthetic valve No Positive True positive Completed IE treatment 
67/M E. faecalis Rectal wall thickness No Positive True positive Therapy prolonged  
Found origin of IE 
70/M A. 
actinomycetemcomitans 
 Brain embolism  Yes Positive True positive 
 
Therapy prolonged 
80/F E. faecalis Rectal wall thickness Yes Positive True positive Completed IE treatment 
33/F Group G streptococcus Right atrium emboli Yes Positive True positive Completed IE treatment 
83/M E. faecalis Pacemaker No Positive True positive Completed IE treatment 
55/M S. gordonii Non-significant uptake No Negative True negative Completed IE treatment 
76/V E. faecalis Non-significant uptake No Negative True negative Completed IE treatment 
83/F P. aeruginosa Non-significant uptake No Negative True negative Completed IE treatment 
39/F S. aureus Non-significant uptake No Negative True negative Completed IE treatment 
73/F S. viridans Non-significant uptake  No Negative True negative 
 
Completed IE treatment 
53/M S. viridans Non-significant uptake  No Negative True negative 
 
Completed IE treatment 
36/M S. gallolyticus Non-significant uptake No Negative True negative Completed IE treatment 
51/M E. faecalis Non-significant uptake No Negative True negative Completed IE treatment 
30/M S. anginosus Non-significant uptake No Negative True negative Completed IE treatment 
62/F S. epidermidis Non-significant uptake No Negative True negative Completed IE treatment 
83/M S. aureus Non-significant uptake No Negative True negative Completed IE treatment 
45/M E. faecalis Non-significant uptake No Negative True negative Completed IE treatment 
       
60/M S. gallolyticus Left radio  No Negative False positive No modifications 
59/F E. faecalis Diaphragm No Negative  False positive Closer follow-up 
76/F S. aureus Soft tissue No Negative False positive 
 
 
Closer follow-up 
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84/F S. viridans Sigmoid and colon No Negative Incidental finding Colonic adenocarcinoma diagnosed 
65/M P. acnes Left pectoral muscle and lung 
nodule 
 
 
No Negative Incidental finding  Lung adenocarcinoma diagnosed 
70/F S. pneumoniae Multiple lung lesions No  Negative  Incidental finding Lymphocytic interstitial pneumonia 
 
68/M 
 
E. faecalis 
 
Solitary lung nodule   
 
No 
 
Negative  
 
Incidental finding  
 
Lung cancer study 
64/M S. mitis Diverticulosis No Negative Incidental finding Colonic study 
IE, infectious endocarditis; BSI, bloodstream infection; TEE, transesophageal echocardiography. 
* True positives where 18 FDG PET/CT was the first diagnostic tool that identify the complication. 
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The validity values for efficacy of PET-CT for the diagnosis of infectious 
embolism were as follows: sensitivity, 100%; specificity, 80%; positive 
predictive value, 90%; and negative predictive value, 100%. Overall, 27 
patients (57.4%) were classified as true positives.  Only 12 of the 27 
true-positive results (44.4%) were initially identified in the conventional 
extension study, as follows: lung, 3; spleen, 2; brain, 2; rectal wall, 3; 
and aortic prosthetic valve, and pleura (1 each).  
 
In the remaining 15 true-positive cases (55.5%), PET-CT was the only 
initial positive imaging technique: 5 cases of spondylodiscitis (SUVmax, 
5.39), 3 cases of intra/endovascular prosthetic material infection 
(SUVmax, 7.39), 3 cases of septic pulmonary embolism (SUVmax, 3.75), 
2 sigmoid, rectum, and anus lesions (SUVmax, 7.53), 1 case of septic 
spleen embolism (SUVmax, 5.60), 1 case of brain embolism (SUVmax 
7.8) 1 pulmonary valve graft (SUVmax 4.33) and 1 soft tissue around 
the pacemaker (SUVmax, 3.74)(Table 12).These findings resulted in 
prolongation of antibiotic treatment for a mean of 52 days (SD 49 days).  
Spondilodiscitis 
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Twelve patients (25.5%) were classified as true negatives, since both 
PET-CT and conventional imaging techniques excluded the presence of 
complications (Table 2). Median length of therapy in these patients was 
34.5 days (IQR, 12.25-46.5), and all patients remained asymptomatic 
during follow-up. 
 
Comparison of Cases and Controls 
In order to assess the clinical impact of PET-CT in patients with IE, we 
compared the study cases with a historic control cohort (1:2) from our 
database matched for etiology and site of IE. The epidemiological and 
clinical characteristics of cases and controls were similar (Table 11). 
Systematic use of PET-CT led to a statistically significant increase in the 
diagnosis of infectious complications (57.4 % vs. 18.0%; p = 0.0001). 
Although the difference did not reach statistical significance due to the 
low number of cases, PET-CT was associated with a 2-fold reduction in 
the number of relapses (4.2% vs.9.6 % p = 0.25).  
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Hospital stay remained stable, mainly owing to the support of the 
outpatient parental antibiotic therapy program. 
There were 3 false-positive PET results (6.4%) in patients with abnormal 
uptake on their initial PET-CT that was not subsequently confirmed 
(Table 2). The sites included left radius (SUVmax, 3.80), diaphragm 
(SUVmax, 7.56), and soft tissue (SUVmax, 2.15) (Table 12). None of 
them presented associated clinical signs or symptoms, follow-up by 
conventional imaging was negative, treatment was not modified (median 
of 45 days), and all patients remained asymptomatic during follow-up.  
No false-negative results were detected. 
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DISCUSSION 
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I. 
Our very large series, which was collected from different institutions in 
a single country over a short period of time, shows epidemiologic 
changes in IE. Nowadays, IE is a disease of the elderly, with multiple 
morbidity conditions; frequently nosocomial (28.1%) and had very high 
mortality both during admission and during the one-year follow-up. 
Incidence rates of IE have been collected over long periods of time, and 
data based on population studies are scarce. Incidence rates range from 
3-10 cases/100,000 habitants [21, 23, 27, 51, 76] and our figure of 3.5 
IE cases/100,000 habitants in a whole country study is concordant 
with that. 
The underlying conditions of patients with IE have also drastically 
change [20, 21, 51], and most of our cases presented with severe 
comorbid conditions. This population of fragile patients are frequently 
exposed to health care–related and nosocomial complications. In our 
series, 28.1% of the episodes were classified as nosocomial; this 
percentage is similar to that reported by Fernandez-Hidalgo et al [77] in 
a series from Spain (28.4%). 
As well as the epidemiology, clinical presentation of the disease has 
changed, and the signs that were once typical of IE (splinter 
hemorrhages [2.3%], Janeway lesions [2.4%], and Osler nodes [1.9%]) 
are now uncommon. One possible explanation is that IE patients are 
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now diagnosed earlier (86% were admitted ≤ 1 month of the initial signs 
of illness), thus reducing the incidence of immunological manifestations 
[18]. 
On the other hand, we commonly observed complications such as 
respiratory manifestations (41%), kidney failure (39%), neurological 
events (19.7%), osteoarticular symptoms (11.5%), and ocular 
manifestations (6.3%). The rate of embolic events in our series was 29%, 
and although our results are similar to the ones reported by others [18, 
78], we believe that this figure could be underestimated, since the 
extension study depends on the institutional protocol and the 
technology available in each center. The introduction of newer 
diagnostic imaging tools such as PET-CT as part of the diagnostic 
algorithm in patients with IE, as suggested by Saby et al [68], should 
prove to be of great interest in this field. 
A shift in the type of patient with IE has been observed: one major 
change in our series was the very low proportion of IE now occurring in 
IVDU. In Spain, this is due, without question to the very large programs 
to control IVDU´s and particularly the methadone maintenance 
programs [79-82]. Although historically native valve IE in IVDU 
represented an important number of affected patients [83], in our 
series, this population accounted for the smallest group whilst the 
number of patients with prosthetic valve and device IE (37.3%), on the 
other hand, has risen [21, 27]. 
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Microbiological diagnostic tools have changed and improved over recent 
decades and, although etiology was confirmed by blood culture in most 
cases (85.3%), there are still cases in which the etiology is unknown 
(9.1%). Molecular techniques enabled us to establish the etiology in 
20.7% of the negative blood culture episodes that would otherwise have 
been considered IE of unknown etiology. However, even though 
molecular methods have been used to diagnose IE are long time well 
know [84], this diagnostic approach is still not routinely available in all 
diagnostic laboratories. 
As for mortality, IE is a severe disease with a poor outcome. In our 
series, in-hospital mortality was 28.9% and one-year mortality was 
11.2%. It seems that infective endocarditis mortality despite the 
introduction of broad-spectrum antibiotics and new diagnostic tools, 
the mortality of IE has remained close to 25% since the 1970s [20]. The 
only intervention that has shown a major impact on mortality was 
surgery, since it was independently associated with a decreased risk of 
one-year mortality (OR, 0.44); our results agree with those of a recent 
analysis of published studies [85] that shows a significant correlation 
between the rate of early surgery and mortality. 
The most common microorganisms in our series were staphylococci, 
streptococci, and enterococci. Thus, a major change in the microbiology 
of IE is that Enterococcus spp has emerged as the third most important 
group of pathogens and is now responsible for 12.7% of IE cases. Since 
132 
 
 
enterococci have shown the ability to develop antibiotic 
resistance[49],the frequency of E-BSI is growing, and a significant 
percentage of cases are associated with IE, we decided to evaluate a 
novel approach to this increasingly frequent problem [86] and specially 
try to identify factors that enable the early selection of patients  who are 
at risk for enterococcal IE.  
II 
In our institution enterococcal IE is present in 4.3% of all patients with 
E-BSI, 16.7% of patients undergoing echocardiography and in 35.5% of 
those who undergo TEE. A simple, bedside predictive score allowed us 
to identify a subgroup of patients with E-BSI in whom the risk of 
enterococcal IE is very low and who therefore would not require 
systematic TEE. Our results confirm that, as indicated in the American 
guidelines, TEE should be the test of choice when the indication is to 
detect IE, especially if the pre-test probability is high, such as in 
patients with staphylococcal bacteremia, fungemia, prosthetic heart 
valve, or intracardiac device [87]. Although systematic performance of 
TEE is not recommended in patients with enterococcal bacteremia in 
current guidelines, our relatively small percentage of patients with 
enterococcal bacteremia who underwent TEE (25.6%), reflects the real 
daily practice and so far, is the only figure in the literature. In our 
opinion, TEE should also be performed in patients with enterococcal IE 
and a NOVA score >4 points. 
133 
 
 
In many institutions, Enterococcus species is the third most common 
cause of BSI. The main origins are the gastrointestinal tract and 
catheter-related infections[26]. The need to rule out IE in patients with 
staphylococcal bacteremia remains open to debate [88], although some 
authors suggest that it may be unnecessary in 26-28% of patients 
fulfilling specific criteria of uncomplicated BSI [89, 90]. The indication 
for echocardiography is even less clear in episodes of bacteremia caused 
by Streptococcus, Candida, and Enterococcus species [62].  
Current guidelines for the diagnosis of IE [62] include echocardiography 
as a key test for the diagnosis and management of patients with IE; 
however, whether TTE or TEE should be performed first depends on the 
interpretation of a series of complex clinical, microbiological, and 
radiological findings. Although the detection rate for TTE is 
approximately 50%[60], the efficiency of the technique is affected by 
factors such as image quality, presence of previous valve disease or 
prosthetic material, skill of the examiner, and pre-test probability of 
endocarditis. It has been proposed that for patients with a high 
probability of endocarditis, performing TEE provides the highest 
quality-adjusted survival [88]. Our study suggests that most patients 
with E-BSI (those with a score ≥4 points) should undergo TEE (16.7% 
positive).  
We also show that TTE misses >70% of episodes of IE and that those 
patients should undergo TEE. Our risk prediction score (NOVA) 
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provides physicians with an easy-to-use system that could rapidly 
determine which patients with E-BSI may require further studies to 
detect IE, merely by examining the number of positive blood cultures, 
the origin of the bacteremia, previous history of valve disease, and 
auscultation of a heart murmur. 
Our study is subject to a series of limitations. First, as it was performed 
in a single center, the sample size was not as large as it might have 
been. Nevertheless, it is the largest sample reported to date and was 
collected over a long period. Second, since patients with bacteremia 
were previously evaluated by an infectious diseases specialist, selection 
bias should be taken into consideration. Interestingly, despite the 
intervention of the infectious diseases department, the rate of 
compliance with echocardiography recommendations remains low 
(34.4%), and a significant number of patients (1127) with enterococcal 
bacteremia did not undergo TEE, thus limiting the ability of the study 
to estimate the real prevalence of IE. However, a further analysis of this 
population showed that only a very small proportion of patients (1.7%) 
could have had IE and that even without TEE, they were treated for at 
least 4 weeks. Finally, ours is a case-control study and the results 
should be validated in a second cohort and/or prospective study. 
Overall, the NOVA score is particularly useful for identifying a subgroup 
of patients with enterococcal bacteremia who may not need to undergo 
TEE (sensitivity 100%) because of an extremely low risk of endocarditis. 
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We do not aim to put forward a hypothesis on the treatment of 
bacteremia or endocarditis, but believe that treatment should be 
established according to guidelines, predisposing conditions, or clinical 
presentation (e.g. stroke and embolic phenomena) independently of the 
NOVA score. 
The first validation of the NOVA score in an external cohort of patients 
with E-BSI shown that this model is very useful for discriminating 
patients at low risk for IE and therefore, it could be used to select 
patients in whom an echocardiography for ruling out IE could be safely 
obviated. However, a prospective study in which all the patients with E-
BSI will be uniformly studied for IE, using not only echocardiography, is 
needed to definitely validate the NOVA score.      
III 
The outcome of IE is closely associated with the extent of systemic 
embolization and extra-cardiac infection; most relapses are due to 
insufficient duration of original treatment or a persistent focus of 
infection [62]. However, a diagnosis of peripheral septic embolism is 
often challenging. Current guidelines [62] agree that embolic events can 
be totally silent in 20% of cases, especially those affecting the spleen or 
cerebral blood flow, and can only be detected using imaging techniques 
(abdominal and cerebral CT scan). To date, no clear consensus has 
been reached on which imaging technique should be performed or 
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whether imaging should be performed systematically or only in 
symptomatic patients. In many cases, the extension study requires 
multiple tests that are not only time-consuming, but also expensive and 
troublesome for the patient.    
The introduction of PET-CT to investigate tumor extension in oncology 
revolutionized the practice of medicine [63]; the assessment of 
hypermetabolic lesions in the field of infectious diseases is more recent 
[61]. In 2010, Vos et al [64] used PET-CT technology to assess distant 
infectious lesions in 115 neutropenic patients with Gram-positive non-
endocarditic bloodstream infections. Metastatic infectious foci were 
detected in 35% of patients; in half, the diagnosis was not previously 
suspected. Subsequently, PET-CT has been evaluated to investigate 
high-uptake lesions in the heart or in intracadiac devices [68, 91, 92]. 
Studies evaluating the role of PET-CT in ruling out extracardiac 
involvement in patients with endocarditis are mainly case reports [67]. 
Van Riet et al, studied 25 patients with IE and found infectious septic 
embolisms in about 44% of patients [66]; however, the study did not 
have a control group, nor did it attempt to evaluate the clinical impact 
of these findings. Our study showed that 57.4% of patients were 
eventually diagnosed with an infectious complication and that more 
than half (60%) were asymptomatic. PET-CT makes it possible to detect 
infectious embolism throughout the body in a single easily performed 
test (<2 h) that is comfortable for the patient and provides the clinician 
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with whole-body data. Although, it was not the purpose of this study to 
evaluate de heart valve lesions with PET-CT, but to evaluate extra-
cardiac involvement, PET-CT detected 7 of 8 cases of IE related to extra-
cardiac prosthetic material: 3 defibrillators (2 with septic pulmonary 
embolisms and 1 with subcutaneous abscess), 1 aortic graft infection, 1 
extra-cardiac Fontan tube infection, 1 aortic homograft and 1 central 
vein catheter (pulmonary septic embolisms). These findings agree with 
those of Sarrazin et al [92], who also found that PET-CT was a useful 
tool for the diagnosis of cardiovascular implantable electronic device 
infections and assessment of their extension. Gated studies of the 
heart, a previous diet preparation of the patient and a larger acquisition 
time would definitely increase the detection of heart valve lesions, but 
more information is needed on this aspect. 
The systematic performance of PET-CT made it possible to detect other 
diseases, such as cancer, that could be involved in the pathogenesis of 
endocarditis. Although the pathophysiological relationship between 
endocarditis and neoplasm remains unclear, the simultaneous finding 
of both entities is not rare [93]. Thomsen et al, [94] have recently 
proposed that endocarditis is a substantial clinical marker for the 
presence of occult cancer with a standardized incidence rate (SIR) of 
1.61 (CI: 1-5-1.71). In this series, cancer risk in endocarditis patients 
was highly elevated during the first 3 months of follow up (SIR= 8.03; 
95% CI, 6.92-9.26).  In our series, PET-CT enabled early detection of 2 
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tumors (1 lung and 1 colon) in patients with Propionibacterium acnes 
and S. anginosus IE.  
The conventional extension study included 76 imaging techniques (1.61 
tests per patient) that included 27 CT´s, 25 echography´s, 13 x-rays, 5 
MRI´s,  5 gammagraphies and 1 angio-CT. PET-CT is clearly more 
expensive than conventional CT or MRI (€658/patient vs. 
€326.42/patient), although it has considerably improved the diagnosis 
of infectious complications. In 15 of 27 cases (55.5%), PET-CT was the 
only initial positive imaging technique that revealed an infectious 
complication. Based on data from our health authorities [95], the mean 
extra-cost of a major complication of a systemic infection is €20,241; 
therefore, early diagnosis of infectious complications with PET-CT is 
cost-effective. Vos et al, [64] evaluated the cost-effectiveness of routine 
PET-CT in 115 high-risk patients with Gram-positive bacteremia and 
found that the cost-effectiveness ratio was $72,487 per prevented 
death.   
Our study is subject to a series of limitations. First, it was performed in 
a single center, thus reducing the number of patients who could be 
included. Second, early PET-CT could only be performed in 66% of 
patients with infective endocarditis, mainly because of emergency 
surgery and hemodynamic instability, which probably excluded patients 
with the most severe complications. Because of inflammatory changes 
and hemodynamic instability after cardiac surgery, we decided not to 
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perform the test immediately in patients who had recently undergone 
surgery. This problem could be resolved as experience with the 
technique increases. Furthermore, our institution only has 1 PET-CT 
device, and cancer patients have preference on the waiting list. 
Therefore, scheduling was problematic in some cases; however, given 
increasing evidence of the usefulness of PET-CT in patients with 
infectious diseases, we expect this situation to change. Third, PET-CT is 
a highly sensitive test for localizing abnormalities, since results are a 
measure of inflammatory cell activity [96]; therefore, the results could 
increase the risk of false-positive findings. To minimize this effect, we 
performed a discrepant analysis and compared PET-CT results with 
clinical and microbiological data and the results of conventional 
imaging techniques. The most problematic discrepant results were 
those for the 3 patients in whom PET-CT findings could not be 
confirmed by clinical, microbiological, or radiological findings during the 
course of their disease. For the sake of this study we considered these 
results to be false positives. Fourth: to assess the impact of PET-CT on 
mortality or relapse in patients with infective endocarditis a prospective 
randomized study, with a larger number of subjects should be 
performed. 
Overall, our study shows that PET-CT is a more effective way of 
assessing the extension of infection in patients with IE.  
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CONCLUSIONS 
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I. IE remains an infrequent but severe disease that commonly 
presents in older patients with multiple underlying conditions 
and is frequently health care–related.   
 
II. Multidisciplinary groups are essential to optimize the 
management and outcome of IE; so far, the only intervention 
that has shown a major impact on one year mortality was 
surgery. 
 
III. The prevalence of enterococcal IE depends on whether the 
sample comprised all cases among those with E-BSI (4.3%), 
only patients undergoing echocardiography (16.7%), or only 
patients undergoing TEE (35.5%).   
 
IV. Depending on the local prevalence of endocarditis, application 
of the NOVA bedside prediction score could safely obviate 
echocardiography in 14-27% of patients with enterococcal 
bacteremia. 
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V. PET-CT is an effective way of accomplishing the extension 
study in a single test in patients with IE. It is easily performed 
(<2 h) and comfortable for the patient and provides the 
clinician with whole-body data.  
 
VI. PET-CT enables significantly more infectious complications to 
be diagnosed (18.0% vs. 57.4%; p = 0.0001) and its use 
procured a trend toward a reduced number of relapses (9.6 % 
vs. 4.2% p = 0.25) in patients with IE. 
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